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Treatments for aggressive cancers like triple negative breast cancer (TNBC) and 
small-cell lung cancer (SCLC) have not improved and remain associated with debilitating 
side effects. There is an unmet medical need for better, druggable targets and improved 
therapeutics. To this end, we investigated the role of Chaperonin-Containing TCP1 
(CCT), an evolutionarily conserved protein-folding complex composed of eight subunits 
(CCT1-8), in oncogenesis. Our laboratory was the first to report that the CCT2 subunit is 
highly expressed in breast cancer and could be therapeutically targeted. To determine 
whether CCT is a marker of disease progression in other cancers, we analyzed CCT2 
gene expression in liver, prostate and lung cancer, using publicly available genetic 
databases, and confirmed findings by assessing CCT2 and client proteins, like STAT3, in 
tumor tissues by immunohistochemistry. We found that CCT2 was high in all cancers, 
especially SCLC, and correlated with decreased patient survival. We tested CT20p, the 
peptide therapeutic developed by our laboratory to inhibit CCT, on SCLC and primary 
lung cells, finding that CT20p was cytotoxic to SCLC cells. Since SCLC currently lacks 
targeted therapeutics, our work yielded a new targeted agent that could improve lung 
cancer mortality. To establish a mechanism of action for CT20p, we partially knocked 
out CCT2 in TNBC cells, which decreased tumorigenicity in mice and reduced levels of 
essential proteins like STAT3.  To confirm, we overexpressed CCT2 in non-tumorigenic 
cells and conferred tumor-like characteristics such as increased migration and elevated 
STAT3. These studies positioned us to develop and validate a strategy for discovery of 
new small molecule inhibitors of CCT. We thus advanced the field of cancer research by 
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demonstrating that CCT could have diagnostic potential for cancers, such as SCLC and 
TNBC, that are a significant cause of human death and showed that targeting CCT is a 
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The Burden of Cancer  
 
Cancer is the second leading cause of death in the United States and accounts for 
nearly 1 in every 4 fatalities [1, 2]. For the year of 2017, it is estimated that 600,920 
people will die due to cancer in the United States alone (Table1), that’s equivalent to 
1,650 deaths per day [3]. In regards to cancer incidence, it is estimated that 1,688,780 
people will be diagnosed with cancer in 2017, that equates to over 4,600 people being 
diagnosed with cancer daily [3]. The most commonly diagnosed type of cancer in women 
is breast cancer. In the U.S., the chances of a woman being diagnosed with breast cancer 
during her lifetime is 1 in 8 or 12.4% [4]. That’s an increase from the 9.09% 1970’s rate. 
Part of this increase is due to longer life expectancy in addition to increased incidence 
[4]. The most commonly diagnosed type of cancer in men is prostate cancer. The lifetime 
risk of a man developing prostate cancer is 11.6% based on 2012-2014 data. Overall, rate 
of cancer incidence is 20% higher in men than in women, while rate of cancer fatalities is 




Lung cancer is the deadliest type of cancer in the United States and Worldwide, 
being responsible for more deaths than prostate, breast and colorectal cancer combined 
[6]. There are two major classes of lung cancer: non-small cell lung cancer (NSCLC) and 
small cell lung cancer (SCLC). NSCLC is responsible for more than 80% of cases and its 
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further subdivide into three subtypes based on histological characteristics: 
adenocarcinoma (AdC), squamous cell carcinoma (SqCLC) and large cell carcinoma 
(LCC). SCLC accounts for 10 to 15% of cases. SCLC is more aggressive, faster 
spreading, and more likely to recur than NSCLC. It is associated with a 5-year survival 
rate of only 6%, compared to 21% for NSCLC [6]. The 5- year survival rate of lung 
cancer is only 17.8%, which is much lower than the 90.5% and 99.6% survival rates for 
breast and prostate cancer, respectively [2]. Frequently, the symptoms associated with 
lung cancer do not appear until the cancer is advanced, a factor that contributes to the 
severity of this disease. Over 50% of lung cancers are only detected after the tumor has 
metastasized from the primary site, and the 5-year survival rate for these cases are 4% 
[2]. SCLC is a carcinoma of neuroendocrine origin and it is characterized by aggressive 
behavior, fast growth and high metastatic spread [7]. Treatments for SCLC include 
cisplatin and etoposide and although about 75% of tumors respond to chemotherapy, only 
25% show complete response and most patients experience disease relapse [8, 9]. 
Attempts to improve outcome using combination therapy or prolonged regimens, have 




Breast cancer is the second leading cause of death in women [3]. There’s a 12.4% 
risk of a woman developing breast cancer during her lifetime, that is one in eight women 
will be diagnosed with breast cancer [1, 6]. About 90% of deaths caused by breast cancer 
are due to metastatic disease [10]. Metastasis occurs when tumor cells leave the primary 
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site and invade distant, vital organs such as lungs, brain and liver, in which case, 
currently available chemotherapeutics are no longer effective. Breast cancer is a 
heterogeneous disease and while certain subtypes of breast cancer, such as ER+, benefit 
from hormone therapy and are associated with better prognosis, subtypes such as triple 
negative breast cancer (TNBC) are associated with lower survival rate and poor prognosis 
[11]. TNBC affects 17% of breast cancer patients and it is characterized by the absence of 
estrogen (ER) and progesterone (PR) hormone receptors, as well human epidermal 
growth factor receptor 2 (Her2) so patients diagnosed with TNBC cannot benefit from 
hormone therapies or Her2 inhibitors [11]. TNBC is the most aggressive form of breast 
cancer, marked by genomic instability, heterogeneity, high incidence of drug resistance, 
high recurrence rates and increased risk of metastasis. The aggressive biology of TNBC 
and the lack of approved targeted agents have contributed to the challenges associated 





Current treatment strategies for patients diagnosed with cancer include surgery, radiation 
therapy and chemotherapy. Surgery is usually recommended for patients with solid 
tumors that are limited to one area and it is not an option in patients with metastatic 
disease. Radiation therapy can be given with curative, palliative intent or as a 
prophylactic measurement as exemplified by small cell lung cancer patients who often 
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receive prophylactic cranial irradiation to reduce the risk of brain metastases [Takahashi, 
2017 #165]. Traditional chemotherapeutic agents, or cytotoxics, can target the cell cycle 
in a specific manner, being most effective during S or M phase, or in a non-specific 
manner (independent of cell cycle phase). Side effects associated with traditional 
chemotherapy are debilitating and often have a negative impact on the patient’s quality of 
life. Additionally, due to tumor heterogeneity, positive selection of drug-resistant tumor 
subpopulation tumor may lead to tumor recurrence. Resistance to chemotherapies and 
targeted therapies limits the effectiveness of current cancer treatments Oncology drugs 
that go into clinical trial have poor success rates, being three times lower than that of 
cardiovascular disease [13]. There is a fundamental flaw in the way we have looked at 
cancer treatments so far. How can we redefine our approach? 
 
 
The dynamic duo 
 
CT20p: the rationally developed peptide 
CT20p is an amphipathic peptide derived from the last twenty amino acids in the 
C-terminus of the pro-apoptotic Bax [14] (Fig. 1). CT20p had cytotoxicity activity that 
was independent of the parent protein or Bcl-2 overexpression and caused cytoskeletal 
disorganization, loss of adhesion, and cell death [14, 15]. CT20p is membrane 
impermeable but can be encapsulated for delivery to cancer cells in nanoparticles (NPs) 
made from a hyperbranched, polyester polymer (HBPE) [16, 17]. The resulting HBPE-
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CT20p has increased serum half-life in addition to having the potential of being modified 
to contain different groups, which allows targeting of tumor cells. In animal models of 
breast and prostate cancer, treatment with CT20p-NPs caused significant tumor 
regression [18, 19]. In order to determine the target of CT20p, a pull down experiment 
was performed and the target proteins were subjected to mass spectroscopy analysis (Fig. 
2). The top results from the pull down experiment are shown in Table 2 and indicate that 
CT20p interacts with 7 out 8 subunits (numbers 5-11 on the list) of the chaperonin 
containing TCP1 (CCT). Transient overexpression of CCT2 (denoted CCTβ in figure 3) 
in cells with low CCT2 levels, increased susceptibility to the peptide (Fig. 3). 





Figure 1: Amino acid sequence and structure of CT20p 
This figure illustrates the amphipathic nature of CT20p. Polar residues are shown in 
yellow, hydrophobic residues are shown in light grey and basic residues are shown in red. 






Figure 2: Biotin-CT20p pull down  
(A) Biotin-CT20p was used to pull down interaction proteins in MCF-10A and MDA-
MB-231 lysates. Lysates were run on SDS-PAGE, and the gel was silver stained to 
visualize bands. Molecular weights (MW) indicated are in kDa. Four bands, indicated by 
boxes, were excised from MDA-MB-231 Biotin-CT20p and biotin pull downs and 
analyzed by mass spectrometry. All lanes presented were originally run on the same gel, 
but have been rearranged for clarity in this figure. (B-C) To analyze true binding to 
CT20p, proteins also identified in the biotin pull down or control gel sample were 
excluded. This resulted in 114 true binding partners in the 50 kDa band (B), and 81 in the 
90 kDa band (C). (D-E) As a control for the “in-cell” pull down, DiI dye encapulated in 
HBPE-nanoparticles was delivered to viable MCF-10A (D) and MDA-MB-231 (E) cells, 
followed by cell lysis and recovery of bound proteins. CCTβ and p38 were detected by 
Western blot - Reprinted from Clinical Cancer Research, 2016, Volume 22, Issue 17, 
Rania Bassiouni et al., “Chaperonin Containing-TCP-1 Protein Level in Breast Cancer 





Figure 3: CCT overexpression increases the susceptibility of MCF-10A cells to 
CT20p 
(A) MCF-10A and MCF-10A (CCT) cells were subjected to a migration assay for 20 
hours. The premigration area is outlined. (B) MCF-10A cells were transfected to 
overexpress CCTb are denoted here as MCF-10A (b). The levels of CCT subunits were 
examined by immunoblotting in these cells, as well as in MCF-10A and MCF-10A 
(CCT) cells. p38 MAPK is used as a loading control. (C) level of CCTb relative to total 
protein was quantified in the three MCF-10A variants. (D) MCF-10A variants were 
treated with CT20p at a dose of 75 mg/mL for 24 hours. Cell death discrimination was 
determined by staining with Sytox AADvanced and F2N12S, followed by flow 
cytometry. The viable cells are in the lower-right quadrant, and their percentage is 
displayed in bold. As a control, mock-transfected MCF-10A were similarly analyzed. E, 
viability data of the MCF-10A variants was quantified. = *** = p<0.001,   **** = 
p<0.0001- Reprinted from Clinical Cancer Research, 2016, Volume 22, Issue 17, Rania 
Bassiouni et al., “Chaperonin Containing-TCP-1 Protein Level in Breast Cancer Cells 





CCT: the intracellular target 
Chaperones are a group of proteins essential for maintaining proteostasis by 
stabilizing other proteins and helping them reach their native conformation [20]. 
Chaperonins (a class of chaperones) are formed by two rings stacked back-to-back, 
forming a central cavity in which unfolded client proteins are sequestered into and can 
reach native conformation isolated from the cytosol [21]. Chaperonins are further 
subdivided into Group I, present in bacteria, mitochondria and chloroplast, and Group II, 
found in archaea and eukaryotes [21]. The eukaryotic chaperonin containing TCP1 
(CCT), also known as TriC, is a type II chaperonin composed of two stacked rings, each 
ring consisting of eight paralogous subunits (Fig. 4). Subunits of the mammalian CCT are 
named using Greek letters (CCTα - CCTθ) and subunits in yeast are denoted using 
numbers (CCT1-CCT8). Subunits range from 50kDa-60kDa [21, 22]. 
CCT subunits are structural homologues and each subunit comprises an apical 
substrate binding domain, an equatorial ATP binding domain and an intermediate domain 
linking the other two domains (Fig. 5). CCT’s ATP binding domain is extensively 
conserved among the subunits, in contrast with the apical substrate binding domain, 
which is the most convergent [23]. This 1MDa complex folds about 10% of the 
eukaryotic proteome in a ATP dependent manner [24]. The nascent peptide is sequestered 
into the cavity of CCT partially or entirely where energy derived from ATP hydrolysis 







Figure 4: Overall structure of CCT 
Structure of yeast CCT showing the closed conformation of the chaperonin and top view 
showing the arrangement of all eight paralogous subunits. PDB accession number 4V94. 












Figure 5: Ribbon diagram of bovine CCT2 subunit 
General architecture of CCT subunits exemplified by CCT2 from bos tauros. The 
substrate binding apical domain (teal) is linked to the equatorial, ATP binding domain 
(fuchsia) by the intermediate domain, a flexible linker that allows CCT transition from 
open (substrate binding) to closed (ATP binding) forms. Image generated by A.C.C. 





CCT clients  
Although there is much to be learned in regards to CCT’s substrate specificity, a 
study have showed that about 40% of CCT’s substrates are essential and about 90% are 
oligomeric complexes [24]. Studies on CCT client’s diversity using NMR, modeling, XL-
MS and mutagenesis suggest that client proteins contact CCT subunits in their apical 
domain on the same loop [26]. The eight human CCT subunits share 30% homology and 
are most divergent at the apical domain, indicating subunit specialization acquired 
through evolution. Cytoskeletal proteins such as actins and tubulins, can only reach their 
native conformation if CCT mediated [22]. Notably, many of CCT’s client proteins are 
involved in oncogenesis, including Von Hippel-Lindau (VHL), p53, cyclin B and E,  
Cdc20, Myc and Stat3 [27, 28]. Von Hippel-Lindau protein (VHL) is a tumor suppressor 
E3 ligase, crucial to the hypoxia response pathway [29]. Loss of function mutations have 
been associated with hemangioblastomas, retinal angiomas, clear cell renal cell 
carcinoma, pheochromocytoma; pancreatic neuroendocrine tumor [27, 30]. VHL was the 
first non-cytoskeletal protein shown to be a CCT client [31]. The tumor suppressor gene 
TP53 is the most commonly mutated gene in cancers and recent evidence indicates p53 
needs CCT for proper folding [32, 33]. CCT also folds and regulates many cell cycle 
regulatory proteins such as Cyclin E [34], Cyclin B  and Cdc20 [35, 36]. Myc is an 
oncogene involved in the onset of many cancers [37], also folded by CCT. Signal 
transducer and activator of transcription 3 (Stat3) transduces signals of over 40 peptide 
hormones from the cell surface to the nucleus and acts as an oncoprotein in several 
cancers types [28, 38]. Taken together, this indicates that CCT is a key regulator of many 
proteins necessary for the development of several cancers.  
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CCT levels in cancer  
In addition to assisting in the folding of many proteins involved in oncogenesis 
and cancer progression, CCT levels are elevated in many cancer types. As an example, 
the CCT8 subunit was upregulated in hepatocellular carcinoma and played an important 
role in the proliferation of these cells [39]. A similar correlation was observed with CCT1 
(TCP1) and CCT2 in both hepatocellular carcinoma and colonic carcinoma [40] and with 
CCT2 in colorectal carcinoma. CCT1 and CCT2 may be upregulated by driver oncogenes 
that are responsible for tumorigenesis in breast cancer [41]. Our own published studies 
provided evidence that CCT2 is significantly overexpressed in invasive ductal breast 
carcinoma (IDC) and in TNBC cell lines, like MDA-MB-231 [18], as well as prostate 
cancer cell lines [19], suggesting the CCT2 levels could correspond to increased disease 
severity. The elevated levels of CCT subunits in cancer is important in two aspects. 
Firstly, CCT levels can be used as a biomarker in the clinical setting for early diagnosis 
of multiple types of cancer as well as a potential marker of disease severity. Secondly, 
due to its elevated levels in cancer cells compared to normal ones, CCT is also a 
promising target for cancer therapy.  
We suggest that by targeting multiple aspects involved in cancer progression 
(versus a single mutation or pathway) the probability of recurrence and resistance is 
greatly diminished. Cancer cells have higher demand for many of CCT’s client proteins, 
therefore CCT inhibition will prevent the proper folding of key cancer related proteins, 




Table 1: Estimated new cases and deaths due to cancer for 2017  
  Estimated New Cases Estimated Deaths 
Primary site Total  Males Females Total  Males Females 
All sites  1,688,780 836,150 852,630 600,920 318,418 282,500 
Breast  255,180 2,470 252,710 41,070 460 40,610 
Prostate  161,360 161,360 - 26,730 26,730 - 
Lung and 
Bronchus 222,500 116,990 105,510 155,870 84,590 71,280 
        




Table 2: Proteins identified by mass spectrometry to interact with CT20p  
 
Reprinted from Clinical Cancer Research, 2016, Volume 22, Issue 17, Rania Bassiouni et al., “Chaperonin Containing-TCP-1 
Protein Level in Breast Cancer Cells Predicts Therapeutic Application of a Cytotoxic Peptide”, with permission from AACR  
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CHAPTER 2: TARGETING THE CHAPERONIN CONTAINING 
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Cancer remains a leading cause of death, with breast, lung, prostate, and 
colorectal among the top four cancers in terms of new cases diagnosed and estimated 
deaths [42]. Most cancer-related deaths are due to metastatic disease, when the primary 
cancer spreads to vital organs like the brain, bone, or liver. A significant impediment to 
finding effective treatments or better ways to detect and diagnose cancers, especially 
metastatic cancers, is tumor heterogeneity. Genomic instability, together with selection 
pressures from the tumor micro-environment, are among the factors that produce genetic 
and phenotypic differences in patients’ tumors and even within the same tumor (intra-
tumor heterogeneity). A case in point is small cell lung cancer (SCLC). SCLC accounts 
for about 15% of lung cancer cases and is characterized by genetic alterations and a high 
proliferative index as well as early metastatic spread [8]. SCLC is an aggressive disease, 
and while responsive to initial treatments, patients later succumb to the disease, which is 
associated with a high rate of relapse and recurrence [43, 44]. SCLC can be further 
classified as limited stage (LS-SCLC) if the disease is confined to one hemithorax and 
regional nodes, or as extensive disease (ES-SCLC) if the cancer has spread to distant sites 
[45, 46]. This classification helps determine the treatment plan for SCLC patients, 
whether surgery and/or prophylactic cranial irradiation (PCI) are recommended. The 
first-line treatment for any stage of SCLC is etoposide-platinum based chemotherapy; 
however, patient survival decreases upon disease recurrence, largely due to the 
development of chemoresistance [9, 11, 43]. Although SCLC is a good candidate for 
targeted therapies, clinical trials testing new targeted chemotherapeutics for SCLC 
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patients have been unsuccessful. As an example, a recent clinical trial using 
bevacizumab—an angiogenesis inhibitor targeting the vascular endothelial growth factor 
(VEGF)—in combination with etoposide-platinum based chemotherapy for SCLC 
patients, concluded that the addition of bevacizumab did not improve patient overall 
survival [47]. In comparison, in non-small cell lung cancer (NSCLC) patients, modest 
results were achieved with angiogenesis inhibitors like bevacizumab when used in 
combination with chemotherapeutics to treat metastatic patients [48, 49].  While there is 
renewed hope of developing new cancer drugs, especially with the recent focus on 
immunotherapies, the challenges of achieving a molecularly targeted treatment that 
provides real benefit for patients with cancers like SCLC are substantial. Central to these 
challenges is the need to identify druggable molecular alterations through a better 
understanding of the basic biology underlying these aggressive cancers.  
The molecular landscape underlying the heterogeneity of cancers like SCLC is far 
from understood and complicates cancer drug discovery. While SCLC has not undergone 
extensive molecular subtyping, it is characterized by a high mutation rate and genomic 
instability. Inactivation of TP53 and RB1 [50], along with alterations of MYC, NOTCH, 
and the PI3K/AKT/mTOR pathways, are among the key genetic changes associated with 
SCLC [51]. Other genes less frequently mutated in SCLC include EGFR [52], KIT [53], 
MET [54, 55], and heat shock proteins [56]. These genes are also commonly mutated in 
other cancers. [57]. Using targeted agents to inhibit these pathways is the goal of many 
studies, but recent findings suggest that single target agents are less effective, and that 
combination therapies, hitting multiple pathways, are more successful in preventing 
cancer relapse and drug resistance in patients [58, 59]. A drawback for combination 
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approaches, however, is the potential for increased drug-related off-site toxicities. A 
rational approach would be to inhibit protein-folding, which could impact multiple 
pathways while using a single inhibitory agent. Chaperonin-containing TCP-1 (CCT) or 
T-complex 1 ring protein (TRiC) is an evolutionarily conserved macromolecular complex 
involved in folding about 10% of the cell proteome [21]. Many of the gene products 
deregulated in cancers such as SCLC (e.g., MYC, TP53, CCNE, KRAS, HSP90, ESR1, 
and NOTCH) are CCT client proteins [60], suggesting a role for the involvement of CCT 
in the development of cancer, driving the need to better understand its contribution to 
malignant transformation. 
Collective evidence suggests that CCT may be upregulated in a broad range of 
cancers. CCT is a hetero-oligomeric complex composed of two rings formed by eight 
subunits [61]. Each CCT subunit, named CCT1-8 (or CCT-θ), is found at a fixed 
position in the ring [21]. Protein folding occurs within a central chamber formed by the 
rings and is mediated through the opening and closing of a lid structure in an ATP-
dependent fashion [62, 63]. A study examining CCT and its activity in cancer cell lines 
revealed that while these cell lines had varying reliance on the protein-folding activity of 
CCT, it was more impactful in cancer cells than in normal cells [64]. As an example, in 
hepatocellular (HCC) carcinoma, the CCT8 subunit was upregulated and played an 
important role in the proliferation of these cells [39]. A similar correlation was observed 
with CCT1 (TCP1) and CCT2 in both hepatocellular carcinoma and colonic carcinoma 
[40], as well as with CCT2 in colorectal carcinoma. In breast cancer, CCT1 and CCT2 
may be upregulated by driver oncogenes that are responsible for tumorigenesis [41]. Our 
own published studies provided evidence that CCT2 is significantly overexpressed in 
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invasive ductal breast carcinoma and in triple-negative breast cancer (TNBC) cell lines, 
like MDA-MB-231 [18], as well as prostate cancer cell lines [19]. This suggests that the 
CCT2 levels could correspond to increased disease severity.  
The elevated expression of different CCT subunits in cancer is intriguing on two 
fronts. First, CCT levels may be useful as a biomarker in clinical settings. Potentially, 
CCT could be detected as an early diagnostic marker in cancers such as SCLC. Or it 
could be used for the diagnosis of disease severity in cancers like breast cancer, in which 
levels of CCT2 correlated with disease progression, as we have previously demonstrated 
[18]. Second, CCT is a promising target for cancer therapy, as depletion of CCT in cancer 
cells caused cell cycle arrest and growth inhibition [39, 41]. In previous studies, we 
showed that an amphipathic peptide called CT20p, derived from the last twenty amino 
acids of Bax, had cytotoxicity activity that was independent of the parent protein or Bcl-2 
overexpression and caused cytoskeletal disorganization, loss of adhesion, and cell death 
[14, 15]. CT20p, while being membrane impermeable, can be readily encapsulated for 
delivery to cancer cells in nanoparticles (NPs) made from a hyperbranched, polyester 
polymer [16, 17]. In animal models of breast and prostate cancer, treatment with CT20p-
NPs caused significant tumor regression [18, 19]. The mechanism of action of CT20p is 
likely inhibition of CCT, as overexpression or deletion of the CCT2 subunit altered the 
capacity of the peptide to kill cells [18]. In the work presented herein, we examined the 
protein levels of CCT in tissue samples of liver, prostate, colon, and lung cancer to 
determine whether CCT subunits were highly expressed in these cancers. We also sought 
to determine whether inhibition of CCT through treatment with CT20p could impact CCT 
client proteins needed for cancer progression.  To that end, we focused on STAT3, since 
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this transcription factor is a CCT client protein [28], is constitutively active in many 
tumors [38], and is a predictor of poor prognosis in cancer [38, 65]. Our analysis revealed 
SCLC to be a promising model to study the role of CCT in cancer, as well as a likely 
candidate to benefit from CCT-targeted therapy. 
 
 
Materials & Methods 
Immunohistochemistry 
Tissue microarrays (TMAs) used in this study were obtained from US Biomax, 
Inc. Their catalog numbers are as follows: CO484a (colonic carcinoma), PR803b and 
PR631 (prostate carcinoma), BC03118 (hepatocellular carcinoma), LC726b, LC802a, 
LC802c, and BC041115a (lung carcinomas) and BN501 (normal tissue array). Each 
TMA contained varied numbers of patient tissue cores as well as normal tissue 
corresponding to the specific cancer type being analyzed. Please refer to Table 3 and 4 
for the number of samples per cancer type. Information about the tissue type, TNM score, 
tumor grade, and stage were provided with the samples. ΤΜΑs were stained for CCT2 
using anti-CCTβ antibody (LS-B4861; LifeSpan Biosciences). TMA LC802c was stained 
in parallel for CCT2 and Stat3 (anti-Stat3 antibody ab32500; Abcam).  Primary 
antibodies were diluted 1:100 in Antibody Diluent (Leica). Staining of tissue arrays was 
performed by a Bond-Max Immunostainer (Leica), with an epitope retrieval buffer of 
EDTA pH 9.0 (Leica). Polymer Refine Detection reagents (Leica) were used, which 
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include a hematoxylin counterstain. Image acquisition and scoring of staining was 
performed by a surgical pathologist as previously published [18] 
 
Cell lines and culture condition 
NCI-H1882 (ATCC CRL-5903), NCI-H1048 (ATCC CRL-5853), NCI-H1105 
(ATCC CRL-5856) and NCI-H719 (ATCC CRL-5837) were cultured in HITES medium 
supplemented with 5% FBS (Gemini). NCI-H1417 (ATCC CRL-5869) was cultured in 
RPMI-1640 in 10% FBS.  MCF 10A (ATCC CRL-10317) cells were cultured in 
Mammary Epithelial Cell Growth Media using MEGM bullet kit (Lonza). THLE-2 
(ATCC CRL-2706) cells were cultured in Bronchial Epithelial Cell Growth Media using 
BEGM bullet kit (Lonza) without the supplied epinephrine, supplemented with an extra 5 
ng/mL EGF (Corning), 70 ng/mL phosphoethanolamine (Sigma) and 10% FBS. AC16 
Human Cardiomyocyte Cell Line (Millipore-Sigma) was cultured in AC16 expansion 
medium [66]. All media contained 1% antibiotic antimycotic solution (Corning). Cells 
were grown in a humidified 37 incubator with 5% carbon dioxide. All experiments with 
listed cell lines were performed within 4 months of receiving them using low passage 
number cells. Viability was routinely assessed by trypan blue exclusion (Gibco). Table 5 







CT20p (VTIFVAGVLTASLTIWKKMG) was commercially synthesized 
(Biopeptide Co., Inc) at >98% purity, with the N- and C- terminals capped with acetyl 
and amine groups, respectively.  For cellular delivery, CT20p was encapsulated in 
hyperbranched polyester nanoparticles (HBPE-NPs) as previously described [14, 15, 17].  
Typically, a peptide loading of 0.15 µg CT20p to 1 mg polymer is achieved. Stat3 




Cytotoxicity experiments: the indicated adherent cell lines were seeded in 96 well 
plates at the recommended seeding density and treated at 70-80% confluency. Suspension 
cell lines were transferred to a 96 well plates in 70% of final well volume, using fresh 
medium. Adherent cells were treated by replacing the well medium with medium 
containing CT20p-HBPE-NPs or Stat3 inhibitor VI at final treatment concentration. 
Suspension cells were treated in 30μLs (3.34X concentration), 24 hours after being 
transferred to 96 well plate. The concentrations selected for CT20p-HBPE-NPs 
treatments were 75 μg nanoparticle/mL 150 μg nanoparticle/mL. The concentrations of 
Stat3 inhibitor VI (S31-201) used were 50μM and 100μM, based on product description 
overview regarding effective concentration of < 100μM (Calbiochem, 573130). 
NCI­H1882 cells were treated for 16 hours with 150 μg/mL CT20p-HBPE-NPs, in 
parallel with untreated control, which received medium only. Cells were lifted, washed in 
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1XPBS and frozen at -80ºC until lysate preparation.  NCI-H1048 cells were treated for 6 
hours before being lifted for lysate preparation.  
 
 
Measuring cell viability  
Cytotoxicity of cells treated with CT20p-HBPE-NPs or Stat3 inhibitor VI was 
determined by adding Calcein-AM and ethidium homodimer (Live/Dead Thermofisher) 
48 hours post treatment and measuring signal intensity using GFP and TexasRed filter 
cubes respectively. Signal intensity and image acquisition were obtained using Cytation5 
(Biotek) and Gen5 software. Per well, three distinct, non-overlapping areas were imaged 
using a 4X phase objective without and with each appropriate filter. Because suspension 
cells grow in clusters, determining cell number using the “cellular analysis” feature is 
suboptimal. We use image analysis to determine GFP and TexasRed mean fluorescent 
intensity. Threshold values were employed when appropriate to eliminate background 
signal. All the data points generated per condition are averaged and used to calculate the 
ratio between intensity from GFP (live cells) and TexasRed (dead cells). Only 





Cell pellets used to make protein lysates were washed in 1X PBS (Corning) and 
frozen at -80̊ C for at least 1 hour prior to lysis. Lysates were obtained by quickly adding 
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ice cold NP-40 Lysis Buffer (50mM K+HEPES pH 7.5, 150mM NaCl, 1% NP-40, 1mM 
EDTA) with freshly added Halt protease inhibitor (Thermo, 78438) immediately after 
pellets were removed from the -80̊ C. Lysis took place on ice for 20 minutes with gentle 
and intermittent vortexing intervals. Lysates were cleared by centrifuging at 12,000 x g 
for 10 minutes, at 4̊ C. Soluble lysates were stored at -20̊ C for no longer than 3 months. 
Freeze/thaw cycles were minimized to avoid protein precipitation and degradation. 
Proteins in the lysates were resolved by SDS-PAGE and transferred to Immobilon-FL 
PVDF membrane (Millipore IPFL00010). Prior to blocking, membranes were stained for 
total protein using Revert (LI-COR) and imaged on Odyssey (LI-COR) using the 700 
channel. After blocking, blots were probed with primary antibodies against CCT2 (anti-
CCTβ, Millipore), CCT4 (anti-CCTΔ, Abcam), CCT5 (anti-CCTε, Abcam), and STAT3 
(anti-Stat3, Abcam), followed by 1-hour incubation with secondary antibodies IRDye 
800CW and/or IRDye 680CW (LI-COR) at a 1:10000 dilution. Bands were visualized by 
NIR fluorescence detection using Odyssey (LI-COR). Relative protein quantification was 
performed with Image Studio software (LI-COR). The signal obtained for proteins of 
interest were normalized to total protein content using Revert (LI-COR) image as 
follows: first, total protein quantification was performed using the 700nm channel, using 
all the protein transferred onto the blot after Revert staining. Second, lane normalization 
factor (LNF) was calculated by dividing the signal of each lane by the signal from the 
lane with highest signal. Third, target signal was determined. Normalization was 
performed by dividing the signal from each target by the LNS. Immunostaining was 
performed with a minimum of two biological replicates and at least three technical 






Experiments were performed at least three times, in duplicates or triplicates, 
where appropriate. Data representative of experiments were selected for this publication.  
TMA data is expressed as means and standard deviation, whereas blots and Live/Dead 
assay data is represented as means and standard error. One-way ANOVA was used to 
compare mean scoring between the different groups defined by various tissue parameters 
as well as signal intensity ratio in treated cells. Tukey’s multiple comparison test was 
used to compare significance between individual groups.  For CT20p treatment analyzed 
by immunoblot, unpaired, two-tailed t-test was used to calculate significance between 
untreated and treated samples. Calculations were performed with GraphPad Prism 
software (GraphPad). Statistical significance was defined as p < 0.05. Datasets generated 
in the current study are available in the Kaplan-Meier Plotter (KMPlot) repository [67, 







CCT2 is overexpressed in lung cancer patient tumors and correlates with decreased 
survival. 
CCT is a macromolecular complex composed of eight subunits, which we will 
refer to by number (CCT1-8) hereinafter. Our previous studies with breast cancer [18] 
revealed that the CCT2 subunit was overexpressed in tumor tissues as compared to 
normal tissues, was increased with advanced disease, and was inversely correlated with 
patient survival.  To determine whether CCT2 was elevated in other cancers, we 
evaluated CCT2 protein levels in several human tissue microarrays (TMAs) for lung, 
colon, hepatocellular, and prostate carcinomas by immunohistochemistry (IHC). We 
found that lung, liver, and prostate tissues had significantly higher levels of CCT2 as 
compared to matched normal tissue (Fig. 6A,B, and E,F Fig. 7A,B). Our findings for 
colon cancer were inconclusive due to high background staining of normal colon tissue 
(Fig. 6I). In liver carcinomas, CCT2 levels were higher in both subtypes analyzed (HCC 
and cholangiocellular carcinomas) as compared to normal hepatic tissue (Fig. 6A-B). 
This difference was statistically significant (p<0.05) in HCC. We also analyzed HCC 
according to grade, as high grade HCC is associated with poorer prognosis [69], and 
observed a progressive increase in CCT2 staining with increasing grade (Fig. 6A). In 
prostate adenocarcinoma, we observed significantly increased levels of CCT2 as 
compared to normal prostate tissue (Fig. 6E). Because increased stage indicates higher 
severity of disease and poorer prognosis, we also analyzed CCT2 levels in prostate cancer 
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by stage and observed a trend of increasing CCT2 staining with increasing stage (Fig. 
6E). Mining databases like The Cancer Genome Atlas (TCGA) and the Human Protein 
Atlas confirmed our findings that high expression of CCT2 occurs in liver and prostate 
cancer and is associated with unfavorable prognosis (Fig. 6C,D and G,H). However, in 
colon cancer, high levels of CCT2 were associated with improved prognosis, although 
this result was not statistically significant (Fig. 6J). 
We next assessed the levels of CCT2 in various subtypes of lung cancer by 
evaluating staining intensity in 236 tissue microarray cores containing cases of 
adenocarcinoma, carcinoid, SCLC, and squamous cell lung carcinoma (SqCLC) (Table 
3). This was then compared to normal lung tissue. All lung cancer subtypes examined had 
significantly higher levels of CCT2 as compared to normal tissue (Fig. 7A).  
Representative images of CCT2 staining in normal lung tissue, SqCLC, and SCLC are 
provided in Figure 7B. We selected SqCLC and SCLC to study in greater detail because 
together, these two lung cancer types represent 35%-45% of all cases [3] and both scored 
significantly higher than normal tissue for CCT2 (Fig. 7A). To determine if CCT2 levels 
increased with disease progression in these two lung cancer subtypes, we grouped TMA 
cores according to their TNM classification (Figure 7C-D) or stage (data not shown) and 
found no statistically significant differences among the groups analyzed. Essentially, 
CCT2 levels were higher than normal lung in these lung cancer subtypes and independent 
of stage or grade. To investigate if CCT2 levels correlated with survival in lung cancer 
patients, we used the publicly available Kaplan-Meier plotter database to generate 
survival data in all lung cancer patients that expressed high levels of CCT2 mRNA. We 
found that there was a statistically significant correlation (p = 0.0031) between decreased 
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survival of grade III lung cancer patients and CCT2 expression, with a 30-month 
difference in survival between the higher expression patient cohort and the lower 
expression patient cohort (Fig. 7E). These results were confirmed with the TCGA 
database. 
We and others previously reported a correlation between high levels of CCT 
subunits and disease progression in breast [18], hepatocellular and colonic carcinoma,  
and gallbladder squamous/adenosquamous carcinoma [70]. To our knowledge, however, 
no other groups have published a correlation between lung cancer and CCT levels. To 
address this gap, we selected this cancer type to investigate further 
 
 
SCLC cell lines express varied levels of CCT2, CCT4, and CCT5 subunits and were 
susceptible to killing by CT20p. 
About 95% of SCLC patients have TP53 mutations [71]; therefore, as 
representative cell lines for our studies, we chose four SCLC cell lines containing 
common TP53 mutations and one SCLC cell line with wild-type TP53 (Table 5). To 
assess CCT expression in the SCLC cell lines, we determined the basal protein levels of 
the subunits CCT2, CCT4, and CCT5 by immunoblot (Fig. 8A-C). The levels of assayed 
subunits were normalized to total protein by staining the membrane prior to blocking. 
Figure 8D provides a representative image of the membrane stained for total protein. The 
cell line NCI-H1048 had the highest level of all five cell lines assayed for CCT subunits 
(Fig. 8A-C). In contrast, NCI-H719 had the lowest level of CCT2, CCT4, and CCT5 (Fig. 
8A-C). The levels of CCT subunits in cell lines NCI-H1882, NCI-H1417, and NCI-
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H1105 were in between those of the highest and lowest SCLC cell lines (Fig. 8A-C). For 
a qualitative analysis of relative levels of the assayed CCT subunits, we normalized the 
signal from all cell lines to the signal from cell line NCI-H1048 for each CCT subunit 
assayed. We then combined the data into one graph to aid visualization (Fig. 8E). It is 
important to note that this comparison is only qualitative since different antibodies were 
used to detect each subunit. The relevant knowledge we gained from these experiments is 
that we can now detect protein level differences of each CCT subunit among the selected 
cell lines. As a quality control check for our protein lysates, we also assayed basal levels 
of wild-type (WT) or mutant p53 in these cell lines and found that NCI-H719 cells had 
the highest and NCI-H1417 cells had the lowest levels of mutant p53, which confirmed 
the data set available at the ATCC website (Fig. 9A-B).    
Our previous published work showed that CT20p is selectively cytotoxic to breast 
cancer cells, and that modulating the levels of CCT2 by inhibition or overexpression 
regulated the susceptibility of cells to killing by CT20p [18]. Hence, it is likely that 
CT20p’s primary mechanism of action is inhibition of CCT. To deliver CT20p to cells, 
we encapsulated the peptide in nanoparticles made from a hyperbranched polyester 
polymer (CT20p-NPs). These nanoparticles are approximately 80 nm in diameter, 
monodispersed and spherical as we have shown in our previous publications [14, 15, 18, 
19]. Peptide loading efficiency was estimated to be 0.15 g CT20p per mg polymer.  
These nanoparticles are negatively charged and we confirmed uptake by all SCLC cells, 
using nanoparticles loaded with the fluorescent dye DiI (Fig. 10). All cells were treated 
with 75 and 150 g/mL of CT20p-NPs (based on polymer amounts) for 48 hours and 
live/dead cells detected with two probes to assess intracellular esterase activity (Calcein 
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AM) for live cells and plasma membrane integrity (ethidium homodimer) for dead cells.  
Live cells fluoresced green, while dead cells fluoresced red. The cell line most 
susceptible to CT20p treatment at the two doses tested was NCI-H1048 (Fig. 11B), which 
also displayed the highest levels of all three CCT subunits (Fig. 8A-C). The cell line with 
the lowest amount of all three CCT subunits, NCI-H719, was also killed by CT20p 
treatment but to a lesser extent (Fig. 11E). Interestingly, the only cell line with WT p53, 
NCI-H1882, had the second lowest levels of CCT subunits but was also highly 
susceptible to CT20p treatment (Fig. 11A) This suggests that loss of p53, a CCT client 
protein, could contribute to cell death in this line. Hence, total levels of CCT may not 
always be as important as the outcome of CCT protein folding activity. The two cell lines 
with high CCT2 levels but lower levels of the other subunits, NCI-H1417 and NCI-
H1105, were susceptible to CT20p, more so for NCI-H1105 (Fig. 8C-D, Fig.11C-D). 
These results indicate that while all SCLC cell lines were killed by CT20p-NPs, those 
like NCI-H1048 that upregulated multiple CCT subunits were more sensitive to killing by 
the peptide.  We also observed that in a number of these cell lines, the cells tended to 
aggregate or cluster (NCI-H719, NCI-H1882), which also decreased upon treatment with 
CT20p (Fig. 11E,A). This is important as we have shown that CCT inhibition through 
CT20p reduces actin and tubulin, which are cytoskeletal components that are CCT client 
proteins [15, 18]. Additionally, of the three SCLC cell lines with the highest levels of 
CCT subunits (NCI-H1048, NCI-H1417, and NCI-H1105), those derived from metastatic 
sources were more susceptible to killing by CT20p than those derived from a primary 
tumor source. These results are summarized in Table 7. 
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CCT2 levels correlate with STAT3 levels in SCLC patient tissues. 
CCT is responsible for folding ~5-10% of the cell’s proteome [24] and many of 
its client proteins are involved in oncogenesis; however, the full CCT interactome 
remains to be discovered [60]. To determine whether CT20p treatment results in 
decreased CCT client proteins, we evaluated STAT3 because this transcription factor is 
frequently involved in oncogenesis [72] and its biosynthesis and activity is directly 
regulated by CCT [28]. To demonstrate a correlation between STAT3 and the levels of 
CCT2 in tumors from SCLC patients, we used TMAs containing SCLC tumor cores 
(Table 3) for analysis of both CCT2 and STAT3. We found that the levels of STAT3 
consistently correlated with CCT2 (Fig. 12A) in most SCLC patient tumor tissues. 
Representative images of two STAT3/CCT2 pairs showing lower score (score 2 and 3) 
and high (score 4) are in Figure 12B. Next, we assayed total STAT3 protein levels in 
SCLC cell lines and determined that STAT3 was detectable in all five cell lines with the 
highest levels in NCI-H719 (Fig. 14A). To investigate the effect of CT20p-NPs treatment 
on the levels of total STAT3, two adherent SCLC cell lines that were most sensitive to 
the peptide, NCI-H1882 and NCI-H1048, were subjected to treatment with the peptide 
for 16 hours and 6 hours respectively. These times were chosen in order to obtain enough 
viable cells for high quality cell lysates. Protein lysates were not effectively recovered 
from SCLC cells treated with CT20p-NPs beyond 16 hours, indicating that most cells 
after treatment are likely dead or dying. CCT2 and STAT3 protein levels were 
normalized to total protein to control for any proteolysis in the CT20p-treated cells. We 
found that in both SCLC cell lines, STAT3 levels decreased significantly, supporting the 
notion that CT20p could be inhibiting the protein-folding activity of CCT and causing 
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loss of client proteins like STAT3 (Fig. 13A).  We also noted that the levels of CCT2 
itself also decreased, but to a lesser extent.  That CT20p could cause destabilization and 
cause the loss of CCT subunits is intriguing and indicates that more needs to be learned 
about the regulation and formation of the CCT complex.   
We also treated the SCLC cell lines with a STAT3 inhibitor (STAT3 inhibitor VI) 
that binds to the SH2 domain and prevents STAT3 phosphorylation.  Previous published 
studies showed a reduction in tumor cell growth in vitro at doses < 100 M [73, 74]. 
SCLC cells were treated for 48 hours at 50 and 100 M and viability assessed as in 
Figure 11. We found that other than the SCLC line, NCI-H719, the SCLC cells were 
minimally affected by the STAT3 inhibitor (Fig. 14B). This suggests that CT20p was 
more effective at reducing STAT3 levels and killing cells than a typical STAT3 inhibitor 
that targets only the phosphorylation and activation of the transcription factor. 
 
 
Immortalized and actively dividing cells have high levels of CCT2. 
To examine the broader effect of CT20p treatment on other cell lines, we selected 
three immortalized non-cancer cell lines that are typically used as controls for testing 
chemotherapeutics  [75]. The AC16 and THLE-2 cell lines are used to examine cardio 
and liver toxicities. Based on our previously published work, the normal breast cell line 
MCF-10A was also selected. We first determined the basal levels of CCT2 (Fig. 15A) 
and STAT3 (Fig. 15B) and included two SCLC cell lines, NCI-H1048 and NCI-H719, for 
comparison since NCI-H1048 had the highest level of CCT2 and NCI-H719 had the 
lowest (Fig. 8A). Note that Figure 15C contains a representative image of one of the blots 
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used for relative quantification of the target levels as well as the total protein stain used 
for normalization. AC16 and THLE-2 cells had levels of CCT2 that were even higher 
than one of the SCLC cell lines, NCI-H719 (Fig. 15A). This was expected since both 
AC16 and THLE-2 cell lines were immortalized using SV40 oncogene [66, 76]. SV40 
inhibits p53 and Rb1, inactivation of which are hallmarks of SCLC. The conditional 
inactivation of these alleles in mice was sufficient for the mice to develop SCLC [77].  
We also observed a similar trend of high CCT2 levels when cells like the immortalized 
lung cancer cell line, BEAS-2B (data not shown), and normal bronchial epithelial 
(NHBE) or fibroblast cells (NHLF) (Fig. 16) were actively replicating in cell culture, 
likely due to the need for increased CCT client proteins like cyclins. Since it is known 
that NBE cells can cause phenotypic changes when co-cultured with cancer cells [78] 
future studies will investigate CCT levels under co-culture conditions and in senescent 
versus dividing cells to determine the involvement of the chaperonin in modulating the 
behavior of normal and cancer cells. In this regard, in our previous work [18], we found 
that MCF-10A cells can undergo spontaneous epithelial-to-mesenchymal (EMT) 
transformation and that transformed cells exhibit higher levels of CCT2 and are 
susceptible to CT20p treatment as shown in Figure 15D. Treatment with CT20p proved 
toxic to these immortalized cells given their high expression levels of CCT2 (Fig. 
15A,D). Normal tissues, on the other hand, are not immortalized with oncogenes or 
actively dividing, so levels of CCT2 were lower, as we observed with normal lung tissue 
(Fig. 15E) and tissues from other organs such as the heart and liver (Fig. 15E). To 
examine any potential toxicities that could result from CT20p treatment, we performed a 
dose escalation study in mice. We observed no significant alternations in the liver and 
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kidney function of mice and all clinical chemistry values were within reference ranges 
(Fig. 17), nor were any changes in weight, blood in urine or necrosis of organs observed 
(Fig. 17). Hence, these studies suggest that CT20p’s susceptibility is based on the 
expression levels of CCT, as well as the activity of the chaperonin. This could establish a 










Figure 6: Effects of high levels of CCT2 in hepatocellular, prostate and colon 
cancers 
(A, E and I) Levels of CCT2 were assayed in human tumor tissue samples of  
(A)hepatocellular, (E) prostate and (I) colon cancer by immunohistochemistry (IHC) as 
described in Supplemental Methods and Materials. Representative images of different 
staining intensities are shown for (D) hepatocellular (200X) and (H) prostate(400X) 
tissues. Images of stained tissues as well as analysis of staining intensity were performed 
by a pathologist For staining analysis a score between 0-4 was give following a scheme 
previously published in Bassiouni et al (2016). Significance was calculated in reference 
to normal tissue.  p<0.05,   ** = p<0.01,   *** = p<0.001,   **** = p<0.0001. (B, F) 
Survival data for patients with high and low levels of CCT2 were queried using the 
TCGA database trhough cBioPortal ( repository can be found in Supplemental Methods 
and Materials). (B) Kaplan-Meyer plot for HCC patients showing that duplication of 
CCT2 gene decreases survival.(F) Kaplan-Meyer plot for prostate cancer patients 
showing that genomic alterations in CCT2 decreases median survival rate by half. (C,G 
and J) Survival data for patients with high levels of CCT2 was queried using The Human 
Protein Atlas database showing that (C) in HCC patients with high levels of CCT2 the 5-
year survival rate is 25% compared to 52% in patients with low levels of CCT2. (G) In 
prostate cancer, patients with high levels of CCT2 have a 5-year survival rate of 93% and 
patients with low levels of CCT2 have 99% survival rate. (J) In colonic carcinoma, the 5-
year survival rate for patients with high levels of CCT2 is 69% versus 54% for patients 








Figure 7: Analysis of CCT2 staining in lung cancer patient tissue  
(A) The levels of CCT2 were assayed in human tumor tissue samples of different lung 
cancer subtypes by immunohistochemistry (IHC) as described in Materials and Methods. 
Tissue cores were analyzed by a pathologist according to stain intensity and given a score 
between 0-4 as previously published in Bassiouni et al (2016). Significance was 
calculated in reference to normal lung tissue. (B) Representative images of stained human 
tissue microarrays (TMAs) shows the elevated levels of CCT2 in both squamous cell 
carcinoma and small cell carcinoma compared to low levels in normal lung tissue. (C) 
Small cell lung cancer (SCLC) samples were grouped according to TNM score (T1/T2 
and T3/T4) and stain intensity for CCT2 was compared between them. Significance 
indicated is in reference to normal lung tissue. (D) Squamous cell lung carcinoma 
(SqCLC) was also grouped by TNM score (T1/T2 and T3/T4) and CCT2 stain intensity 
was compared. Significance indicated is in reference to normal lung tissue. (E) Kaplan-
Meier plot of lung cancer patients based on CCT2 expression. The survival graph was 
generated using publicly available database (KM plotter; www.kmplot.com).  Data 
analysis was restricted to patients with grade III lung cancer (n=77).  * = p<0.05,   ** = 




Figure 8: Levels of CCT subunits are detected in SCLC cell lines 
Lysates corresponding to five SCLC cell lines were subject to immunoblot analysis for 
(A) CCT2, (B) CCT4 and (C) CCT5. The bar graphs below each corresponding blot, 
shows their relative levels for all five cell lines. Relative quantification was calculated by 
normalizing antibody specific signal to signal obtained from total protein. (D) PVDF 
membrane stained for total protein using Revert (LI-COR). (E) Graph showing relative 
values of the three assayed CCT subunits in each SCLC cell line.  * = p<0.05,   ** = 
p<0.01,   *** = p<0.001,   **** = p<0.0001. Blot images are representative
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Figure 9: Levels of p53 in SCLC cell lines 
Cell lines from the ATCC SCLC p53 Hotspot mutation panel, used in this study, were 
assayed for p53 levels as quality control. (A) Total soluble lysate corresponding to 
indicated cell lines (five human SCLC cell lines and an immortalized lung breast 
epithelial cell line) were assayed for p53 levels (red band). GAPDH was used as loading 
control (green band). (B) Bar graph showing relative quantification of p53 levels which 
were normalized to GAPDH levels as described in Supplemental Methods and Materials. 
(C)Amino acid change due to genomic mutations found in TP53 for each cell line. All 




Figure 10: CT20p NPs co- localize with SCLC cells 
DiI dye (1,1'-Dioctadecyl-3,3,3',3'-Tetramethylindocarbocyanine Perchlorate) 
encapsulated in HBPE-nanoparticles were delivered to viable SCLC cells as described in 
Materials and Methods.  Cells were imaged after 24 hours for fluorescent signal 
indicative of nanoparticle uptake. Column (A) Phase contrast images(4X) (B) Phase 









Figure 11: CT20p is cytotoxic to SCLC cell lines 
Five SCLC cell lines were subject to CT20p treatment at 75 μg/ml or 150 μg/ml for 48 
hrs as described in Methods and Materials. Untreated control received medium only. 
Calcein-AM and ethidium homodimer were added to cell cultures prior imaging to 
indicate live (green) and dead (red) cells respectively. Representative images of (A) NCI-
H1882, (B) NCI-H1048, (C) NCI-H1417, (D) NCI-H1105 and (E) NCI-H719 are shown 
for untreated control and the two doses used. Signal obtained using GFP filter (indicative 
of live cells) was divided by signal detected using TexasRed filter (indicative of dead or 
damaged cells) for each cell line. Bar graphs adjacent to each corresponding cell line 
show the normalized ratios (%live/dead). Cytotoxic effects can be observed by an overall 
decrease in green signal concomitantly to an increase in red signal. * = p<0.05,   ** = 





Figure 12: In SCLC patient tissue, levels of CCT2 correlate with levels of client 
protein Stat3 
(A-B) TMA containing human SCLC tissue was stained for CCT2 and Stat3 in parallel as 
described in Methods and Materials. Tissue cores were analyzed by a pathologist 
according to stain intensity as described previously. (A) Pie chart indicates the number of 
cores which received equal scoring for CCT2 and Stat3 staining, as well as cores which 
received scores that differed by 1 (no cores received scores that differed by more than 1). 
(B) Representative images of corresponding CCT2 and Stat3 stained TMA cores D2 and 






Figure 13: CT20p treatment decreases levels of Stat3 in SCLC cell lines 
(A) Cell lines NCI-H1882 and NCI-H1048 were treated with 75 μg/ml CT20p-NPs for 16 
hours and 6 hours respectively, at which point cells were trypsonized and lysates made. 
Soluble lysates of untreated cells (cultured in parallel with treated cells and lifted at the 
same time) were immunoblotted for CCT2 and Stat3. Bar graphs indicate relative levels 
of CCT2 and Stat3 in control and treated cells calculated as in Figure 8A-C. (B) Image of 
stained PVDF membrane showing total protein corresponding to the samples blotted. 
Signal obtained from total protein was used to normalize CCT2 and Stat3 signal. * = 








Figure 14: SCLC cell lines Stat3 inhibition 
(A) Immunoblot showing relative levels of Stat3 in the five SCLC cell lines. Levels of 
Stat3 shown were normalized to total protein. Calculations are described in Methods and 
Materials. (B) Five SCLC cells lines were treated with Stat3 inhibitor IV at 50μM and 
100μM  as described in materials and methods. The cell line the highest levels of Stat3, 
NCI-H719, had the most significant response. Analysis was performed by averaging 
triplicates and significance was calculated as described in Methods and Materials. * = 








Figure 15: Immortalized cell lines are high expressers of CCT2  
(A-B) Immunoblot of the indicated immortalized cell lines alongside two SCLC cell lines 
for (A) CCT2 and (B) STAT3. (C) PVDF membrane stained for total protein, used for 
normalization of band intensity after antibody probing. (D) Viability of immortalized cell 
lines after 48 hours treatments with CT20p-NPs at indicated and control was assessed 
using Calcein-AM and ethidium homodimer to indicate live and dead cells respectively. 
(E) The levels of CCT2 were assayed in tissue from normal organs by IHC as described 
in Materials and Methods. Representative images of stained TMAs of liver, heart and 














Figure 16: Primary lung cells have high levels of CCT2 
Normal human bronchial epithelial cells (NHBE) as well as normal human lung 
fibroblasts (NHLF) were assayed for levels of CCT2 and susceptibility to CT20p. (A) 
Levels of CCT2 in primary lung cells were high compared to SCLC cell lines. Levels are 
shown as percent of the highest signal (HNLF) and normalization was performed as 
described previously. (B) NHBE cells were treated with CT20p as described in Methods 
and Materials and cytotoxicity detected using Live/Dead (Promega). Signal from 3 wells 
were averaged as means and standard error. Per well, four overlapping quadrants were 












Figure 17: Results from blood chemistry, urinalysis, weight and histology from mice 
treated with CT20p-NPs   
Three male and three female nude mice (6-8 weeks old) were treated with five doses (2.4 
mg/kg, 4.8 mg/kg, 9.6 mg/kg, 19.2 mg/kg, 38.4 mg/kg) of CT20p-NPs over a two week 
period. Treatments were performed on Days 0, 3, 7, 10 and 14 and mice were euthanized 
14 days after the last treatment. (A) Serum of treated mice was sent to Idexx for testing 
for the chemical chemistry panel which assesses kidney and liver function. No statistical 
differences were observed between control and NP-treated mice. Reference table contains 
normal clinical chemistry values adapted from the Animal Care Website at the University 
of Arizona. (B) The weight of mice during treatment was determined at the specified time 
points. (C) Urine analysis was performed using dipstick during treatment at four time 
points as indicated in the table. Results from a representative mouse are shown. (D) 
Histology of treated mice liver and kidney showing no signs of necrosis. Representative 




Table 5: Information on cell lines used in this study:   
 
Table summarizes information pertaining to cell lines used in the experiments in the main manuscript. Information about tissue 
of origin, source (primary versus metastatic sites for tumor derived cell lines), key characteristics and lot number are provided. 
Relevant publications regarding the immortalized cell lines used are provided. 
Supplemental Table S2
Cell line Tissue Source
Lot 
number
NCI-H1882         
(ATCC CRL-5903) 
Lung Metastatic site:Bone marrow 58136167
NCI-H1048         
(ATCC CRL-5853) 
Lung
Metastatic site: Pleural 
effusion
62784665
NCI-H1417         
(ATCC CRL-5869) 
Lung Primary 62007515
NCI-H1105         
(ATCC CRL-5856) 
Lung Metastatic site: Lymph node 63374473
NCI-H719           
(ATCC CRL-5837) 
Lung Metastatic site:Bone marrow 62007616
THLE-2               
(ATCC CRL-2706) 
Liver Liver 64258509
MCF-10A            
(ATCC CRL-10317) 
Breast Breast epithelial 64066742
AC16 (SCC109) Heart Cardiomyocyte RD1606008
Key characteristics/ mutations
Adherent cell line/ RB1 mutation
Adherent cell line - cells grow in colony and 
can form clusters/ RB1, TP53 mutations
Suspension cells - grow in floating clusters/ 
RB1, TP53 mutations







































Suspension cells - grow in floating clusters/ 
RB1, TP53 mutations
Epithelial cells transformed with SV40 
large T antigen [1].
Breast epithelial cells, derived from human 
fibrocystic mammary tissue spontaneously 
immortalized [2]. 
Primary cells from human ventricular 
tissue, were fused with SV40 transformed, 
uridine auxotroph human fibroblasts, 
devoid of mitochondrial DNA [3].
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This table summarizes results on experiments using the five SCLC cell lines obtained from CCT2 blots found in Figure 2, 
CT20p susceptibility found in Figure 3, tumor source, culture type (suspension versus adherent) and key genes containing 
mutations. The criteria for “high, medium and low levels” are summarized on the table itself. In short, for CCT2 levels, figure 
2E was used. Cell lines with signal about 70% were classified as “high”, and below 30% as low, if in between, they were 
considered “medium”. For CT20p susceptibility, average values obtained for untreated, 75μg/ml and 150μg/ml were plotted in 
prism and using linear regression, the IC50 value for each cell line was determined. If the extrapolated IC50 was below 
75μg/ml, susceptibility was considered high, if above 121μg/ml, susceptibility was determined to be low, if in between, cells 






In this study, tissues and cells from various cancers and normal organs were used 
to investigate CCT as a potential biomarker and therapeutic target in cancer treatment.  
We assessed CCT2 subunit protein levels across prostate, liver, and lung cancer tissue 
specimens and found that CCT2 expression levels correlated with disease progression in 
liver and prostate cancers, and CCT2 levels were significantly higher in lung carcinomas 
as compared to normal lung tissue independent of disease stage.  We also showed that 
CCT2 levels were low in normal heart, liver, and lung tissues.  These findings build upon 
our previous discoveries in breast and prostate cancer in which CCT2 levels were 
elevated as compared to non-disease tissues.  Using SCLC cell lines, we demonstrated 
susceptibility to killing by our putative CCT inhibitor, CT20p, which proved more 
effective than a STAT3 inhibitor, and the resulting reduction of CCT client proteins (e.g., 
STAT3) in part addressed the mechanism of action for CT20p. 
CCT belongs to the family of group II chaperonins that are found in eukaryotic 
cells and archaea and consists of eight paralogous subunits that differ mainly at the apical 
domains [61].  Unique to CCT is the formation of hetero-oligomeric complexes and the 
use of an ATP-dependent conformational change to control the opening/closing of a 
built-in lid [22, 61]. Hence, subunit diversity and sequential substrate binding generates 
multiple substrate binding sites that, when coupled to the lid closing mechanism, endow 
CCT with a flexibility to fold many more proteins than its bacterial counterparts [26]. 
This broad range of protein substrates means that 5-10% of newly synthesized proteins 
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may require CCT for folding [24], but also that only part of the CCT interactome has 
been discovered. Given our findings of elevated CCT expression across cancer types, it is 
likely that CCT is responsible for folding more of the cell proteome in cancer or 
transformed cells than in normal cells. There also seems to be a selectivity for CCT 
subunits based on cancer types. For example, CCT3 and CCT8 were overexpressed in 
hepatocellular carcinoma (HCC) [39, 72, 79, 80] and the proteins were detected in the 
plasma from patients, suggesting that CCT3 could be used as a biomarker for screening 
HCC.  We and others found that CCT2 was elevated in breast cancer [18, 41] as well as 
in gall bladder carcinoma [70].  In the current study, in addition to HCC and prostate 
cancer, we also found that CCT2 was increased in SCLC and in advanced stages of 
SqCLC.  Understanding why cancers are selective for CCT subunits may require a better 
understanding of the basis of CCT substrate recognition as well as the discovery of new 
classes CCT substrates, such as those up-regulated in cancer cells.   
As a possible CCT inhibitor, CT20p is one of the first.  While arsenic was shown 
to inhibit CCT function and impair both actin and tubulin filaments [81], other than 
CT20p, only N-iodoacetyl-tryptophan (I-Trp), a synthetic small molecule, has been found 
to disrupt the interaction between CCT and tubulin, causing apoptosis through an ER 
stress-dependent mechanism [82, 83].  In contrast to I-Trp, CT20p does not cause death 
through a traditional apoptotic mechanism [14], which can be downregulated in cancer 
cells;  rather, its inhibitory effects could extend to multiple client proteins that are 
essential for cancer progression [84].  Hence, inhibitors of protein folding have 
therapeutic value since their inhibition can decrease the pool of oncoproteins that cancer 
cells depend on.  As an example, inhibitors of the heat shock protein family (HSPs), 
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Hsp90 or Hsp70, showed significant efficacy in pre-clinical studies [85]. The Hsp90 
inhibitor, Ganetespib, proved effective in SCLC cell lines, causing cell cycle arrest and 
caspase-3 dependent apoptosis [86]. However, human clinical trials in non-small cell 
lung cancer (NSCLC) with molecularly unselected patients were disappointing. While 
some promising results were observed in a cohort of patients with ALK-rearrangements, 
HSP inhibitors overall did not perform as expected from the pre-clinical data. The 
reasons for this could be that inhibition of HSPs may trigger a protective heat shock 
response through activation of heat shock transcription factor 1 (HSF1) and GRP78, 
which blocks the apoptosis of cancer cells. Alternatively, the level of HSP inhibition 
achieved in patients could have been insufficient to kill tumor cells [87]. Patients also 
developed resistance to Hsp90 inhibition due to activation of RAF/MEK/ERK or 
PI3K/AKT/MTOR pathways, requiring the need for combination approaches to make 
Hsp90 inhibitors work [88].  We anticipate that inhibition of CCT with CT20p may not 
result in similar problems because we have no evidence of induction of a heat shock 
response, such as the membrane translocation of GRP78 (data not shown). Further, the 
use of  nanoparticles to deliver CT20p to tumors can achieve therapeutically relevant 
doses [14, 15, 19].  Our data also suggest that CT20p could knock out pathways—such as 
those induced through STAT3—that are linked to growth and survival signaling; hence, 
resistance activated by these pathways may not develop. 
STAT3, which regulates the expression of genes involved in cancer progression, 
is an attractive target for inhibition in SCLC since it is found in primary SCLC tissues 
and in SCLC cell lines [89]. While a number of STAT3 inhibitors have been developed, 
most either inhibit the kinases that phosphorylate and activate STAT3 or they prevent the 
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formation of STAT3 dimers through disruption of the protein’s SH2 domains.  Drugs, 
like the antibiotic doxycycline, inhibit STAT3 in lung cancer cells at the cost of severe 
side effects in patients like nausea, vomiting and diarrhea, rash and sensitivity to sun 
[90]. While there are many STAT3 inhibitors, few have moved into clinical trials and 
none to the clinic. Reasons for this failure are unknown but could be explained by the fact 
that most STAT3 inhibitors target the dimerization or phosphorylation domains; 
therefore, unphosphorylated STAT3 is unaffected and available for activation [91]. Since 
CCT is essential for the synthesis, refolding, and activity of STAT3 [28], inhibitors of 
CCT should also reduce the levels of total STAT3.  Our data show that in SCLC cell 
lines, CT20p reduced STAT3 levels, while these same cell lines were resistant to killing 
with a STAT3 inhibitor. In fact, only one SCLC cell line was susceptible to the STAT3 
inhibitor and also had the highest levels of STAT3.  This cell line was also killed by 
CT20p, likely due to the loss of STAT3 along with other CCT client proteins.    
 Cancers like SCLC are challenging diseases to treat and are typically 
diagnosed at advanced stages.  Systemic treatments are not curative [43]. Molecular 
targeted therapies are promising, despite requiring patients to be pre-screened, but only a 
few targets, like ALK, are associated with clinically relevant inhibitors (e.g., Crizotinib) 
and patients frequently relapse [87].  Our research suggests that therapeutically targeting 
CCT with inhibitors like CT20p could have benefits for SCLC patients. As shown in our 
studies, CCT subunits are overexpressed in SCLC as well as in advanced stages of other 
cancers. We anticipate that each patient will likely have their own unique CCT 
interactome based on the oncogenes that drive their cancer.  The products of many of 
these oncogenes—such as STAT3, KRAS, or MYC—are CCT substrates; hence, each 
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patient whose cancer overexpresses CCT could be treated without the need of molecular 
subtyping the downstream substrates.  So whether a patient’s tumor is driven by STAT3, 
MYC, Notch or a combination, they could still be treated with a CCT inhibitor since the 
chaperonin is essential for these proteins to reach functional status. Our approach, using 
the nanoparticle platform to deliver CT20p, has the potential to reach therapeutic doses in 
tumors and minimize off-site accumulation.  CT20p treatment also has promising use in 
combination approaches with other drugs. Trials with checkpoint inhibitors in SCLC 
resulted in some durable responses [9], generating interest in agents like CT20p that 
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CHAPTER 3: THE EFFECT OF CHAPERONIN CONTAINING 
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Breast cancer is one the most commonly diagnosed cancer types and the second 
leading cause of death in women [42]. Tissue biopsy is typically used to confirm 
diagnosis and classify the tumor according to histological grade, using parameters such as 
the Nottingham Histologic Score and pathologic staging (TMN). Such classification, 
while needed for prognosis, does not always provide information on useful markers that 
can guide targeted therapies. In contrast, molecular classification of breast cancer allows 
for a patient specific treatment plan, which yields improved patient outcome. There are 
five breast cancer molecular subtypes, which are classified according to the levels of 
estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor 
receptor 2 (HER2), claudin and EGFR: claudin-low, basal-like/triple negative, Her2 
enriched, luminal A and luminal B [92].  Cancers with such markers can be treated with 
drugs like Tamoxifen that blocks the effects of estrogen or Herceptin (trastuzumab) 
which works against HER-2 positive cancers. While these treatments are successful, the 
need still exists for the discovery of new therapeutic targets for cancers lacking hormone 
receptors or to improve the use of current therapies in combination approaches. 
Triple negative breast cancer (TNBC) tumors are aggressive and are associated 
with poorer prognosis compared to the ER-positive subtypes [93]. TNBC is marked by 
the absence of ER, PR and Her2 receptor, therefore, patients diagnosed with this type of 
breast cancer are not eligible for hormone therapy or anti-HER2 agents. TNBC represents 
about 17% of all breast cancer cases and is marked by genomic instability, heterogeneity, 
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high recurrence rates and increased risk of metastasis. Patients diagnosed with TNBC 
have limited therapeutic options and a much lower survival rate. To address this issue, we 
previously reported the development and efficacy of CT20p, a cancer specific cytotoxic 
peptide [18]. In the same work, we provided compelling evidence that the intracellular 
target of CT20p is the chaperonin containing TCP1 (CCT) or T-complex 1 ring protein 
(TRiC). CCT is a macromolecular, evolutionarily conserved complex composed of two 
stacked rings, back-to-back, with each ring being comprised of eight distinct subunits 
CCT1-CCT8 or CCTα-θ [94]. All eight subunits share the same basic structure 
containing an equatorial ATP binding domain, an apical substrate binding domain and an 
intermediate domain, linking the other two domains [62]. CCT substrates are sequestered 
into a central chamber, formed by the two stacked rings, where protein folding occurs in 
an ATP-dependent fashion [62, 63]. About 10% of the proteome is thought to interact 
with CCT [24] including CCT’s obligate clients, the cytoskeletal proteins actin and 
tubulin, and cell cycle regulators Cdc20 and Cdh1 [22, 94, 95]. Other client proteins 
include, PLK1 [96], cyclin E [34], the von Hippel Lindau tumor suppressor [31], Stat3 
[28], p53 [33] and MYC [26]. Considerable evidence suggests that CCT has a role in 
oncogenesis and tumor progression [97]. The genes coding for the eight CCT subunits are 
amplified in a variety of cancers [64]. CCT1 and CCT2 are essential for breast cancer cell 
survival and are linked to driver oncogenes responsible for tumorigenesis in breast cancer 
[41]. Our previous work shows that CCT2 is significantly overexpressed in invasive 
ductal breast carcinoma (IDC), in TNBC cell lines, such as MDA-MB-231 and MDA-
MB-436 [18], and in prostate cancer cell lines [19], which suggests that CCT2 levels 
could indicate increased disease severity.  
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For the work presented here, we further investigated the role of CCT2 in 
tumorigenesis to better understand its contribution to cancer progression. Using the 
CRISPR/Cas9 system, we generated breast cancer cell lines with partial inhibition of 
CCT2 (full inhibition was lethal) and using a lentiviral over expression system, we 
produced breast epithelial cells with increased levels of CCT2. As a result, we detected 
changes in tumorigenicity and key CCT client proteins like STAT3.  These findings 
indicated that CCT could be a driver of breast cancer through selective expression of 
subunits like CCT2 that confer increase protein folding activity to provide essential client 
proteins needed by cancer cells to survive, grow and transform. Hence CCT2 could be a 




Materials & Methods 
 
Cell lines and culture conditions 
Cell lines used were MDA-MB-231 (ATCC HTB-26) triple negative breast 
cancer cells and MCF10A (ATCC CRL-10317™) breast epithelial cells. MDA-MB-231 
cells were low passage cells cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) 
(Corning) supplemented with 10% FBS (Gemini) and 1% Penicillin-Streptomycin 
(Corning). MCF10A cells were low passage cells cultured in Mammary Epithelial Basal 
Medium (MEGM-Lonza) supplemented with bovine pituitary extract (BPE), human 
epidermal growth factor (hEGF), hydrocortisone ( all from MEGM bullet kit - Lonza) 
and 1% Penicillin-Streptomycin (Corning). MDA-MB-231 transfected with CRISPR 
gRNA 3 plasmid (GenScript) were cultured in the same medium as WT MDA-MB-231 
with the addition of 0.5 μg/mL puromycin dihydrochloride (ThermoFisher). The 
MCF10A cells transfected with the lentiviral plasmid were cultured in the same medium 
as the WT MCF10A with the addition of 1 μg/mL puromycin dihydrochloride 





Small cohort tissue microarray (TMA) was obtained from Florida Hospital 
(IRBNet# 748165). Large cohort TMAs containing normal breast tissue and breast cancer 
tissue at various disease stages were commercially acquired (BR8013 and BR8017, US 
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Biomax) and contained associated information about the tissue type, TNM score, tumor 
grade, and stage. TMAs were stained for CCT2 using anti-CCTβ antibody (LS-B4861; 
LifeSpan Biosciences) and for STAT3 using anti-Stat3 antibody (ab32500; Abcam). 
Antibodies were diluted 1:100 in Antibody Diluent (Leica). Staining of tissue arrays was 
performed using a Bond-Max Immunostainer (Leica), with an epitope retrieval buffer of 
EDTA pH 9.0 (Leica). Polymer Refine Detection reagents (Leica) were used, which 
include a hematoxylin counterstain. Scoring of staining was performed by a surgical 
pathologist as previously published [18]. 
 
 
Plasmids and primers 
The CRISPR knockout CCT2 CRISPR guide RNA 3, Clone ID: C27761, Vector: 
pSPCas9 BB-2A-Puro (PX459) v2.0 was purchased from GenScript. The lentiviral 
plasmid pLV[Exp]-EGFP:T2A:Puro-EF1A>{hCCT2[ORF023792]*/FLAG} for CCT2 
overexpression was purchased from Vector Builder by Cyagen Biosciences. Envelope 
vector pMD2.G (Addgene 12259) and packaging vector psPAX2 (Addgene 12260) were 
provided by Didier Trono through Addgene plasmid repository.  PCR primers used for 
CCT2 knockdown efficiency were Forward CACTGCCCCTTTAACTGTCA and 





Lentiviral transduction  
Lentiviral plasmid pLV[Exp]-EGFP:T2A:Puro-
EF1A>{hCCT2[ORF023792]*/FLAG} for CCT2 overexpression (Cyagen Biosciences), 
envelope vector pMD2.G (Addgene 12259),and packaging psPAX2 (Addgene 12260) 
were transfected into 293T cells using transfection solution (105 μM Tris, water, 98 mM 
CaCl2, and 1X HEPEs-buffered saline). Supernatants containing the virus were harvested 
24 and 48 hours post-transfection. The virus was concentrated in 15 mL Beckman 
Ultraclear tubes at 4° C 70000 x g for 1.5 hours then resuspended in RPMI 1640 
(Corning). MCF10A cells were plated in 6 well plates and transduced with 50X virus 
stock the following day in MEBM as described above with 8 μg/mL polybrene 
(Millipore). The following day cells were washed twice with 1X phosphate-buffered 
saline (Corning) and medium replaced with MEBM containing 1 μg/mL puromycin. 
CCT2 overexpression was monitored by tracking GFP signal in the transduced cells.  
 
 
CRISPR/Cas9 MDA-MB-231 CCT2 knockdown cell line generation 
CRISPR knockout CCT2 CRISPR guide RNA 3, Clone ID: C27761, Vector: 
pSPCas9 BB-2A-Puro (PX459) v2.0 was designed by the Zhang lab and purchased 
through GenScript. The plasmid was transformed into DH5α E. coli and maxiprepped 
using Invitrogen PureLink HiPure Plasmid Filter Purification Kit Catalog #K2100-15 and 
Invitrogen PureLink HiPure Precipititator Module Kit Catalog #K2100-21 following the 
included protocol. MDA-MB-231 cells were plated in 6 well plates overnight and 
transfected the following day using Mirus Trans-IT® X2 Transfection reagent. 48 hours 
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following transfection the cells were split and placed under selection with 0.5 μg/mL 
puromycin in DMEM.  
 
CCT2 knockdown efficiency  
Measurement of CCT2 genomic cleavage performed using Life Technologies 
GeneArt Genomic Cleavage Detection Kit (Cat# A24372) following the included 
protocol. MDA-MB-231 CCT2 Knockout cells were collected and pelleted for each 
sample and lysed according to protocol. Using the lysate, PCR was performed around the 
region of interest using primers: Forward CACTGCCCCTTTAACTGTCA and Reverse 
AGCTGCTGGATTGTCAACAC. The PCR product was confirmed to be present and of 
the correct size by running on 1.5% agarose gel with control primers to validate the kit. 
Next the PCR product underwent cleavage assay according to the protocol and the final 
product run on a 1.5% agarose gel. Intensity of each band was analyzed using ImageJ 
software to measure relative intensities. The gel image was captured as a TIF and 
converted to an 8-bit black and white image. A histogram of each lane was generated and 
the area of the curve and percent intensity was captured using the wand tool. The relative 




Antibodies for immunoblots include: anti-TCP-1 beta (Millipore,clone F39 P7 
F11 MAB10050 mouse monoclonal (1:1000 WB) , Abcam anti-TCP-1 delta ERP8495(B) 
ab129072 rabbit monoclonal (1:1000 WB), Abcam anti-TCP-1 epsilon EPR7562 
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ab129016 rabbit monoclonal (1:1000 WB), Abcam anti-STAT3 antibody E121-21 
ab32500 rabbit monoclonal (1:1000 WB), Santa Cruz anti-p38α (C-20) rabbit polyclonal 
(1:1000 WB), LI-COR IRDye 680 CW Goat anti-Rabbit IgG (1:10000 WB)and LI-COR 
IRDye 800 CW Goat anti-Mouse IgG (1:10000 WB). For lysate preparation, cell pellets 
were washed in 1X PBS prior freezing and stored at -80° C for at least 30 minutes. Cells 
were lysed by resuspending  in ice-cold NP-40 Lysis Buffer (50 mM K+ HEPES pH 7.5, 
150 mM NaCl, 1% NP-40, 1 mM EDTA) containing 1X protease inhibitors 
(ThermoScientific) on ice for 10-15 minutes. Lysates were centrifuged at 12000 x g for 
15 minutes at 4° C to pellet cellular debris. Supernatant recovered was mixed with 4X 
Orange G loading dye (LI-COR) supplemented with 10% β-mercaptoethanol (Gibco) and 
heated at 99° C for 10 minutes. Proteins were resolved by SDS-PAGE and transfered to 
PVDF membrane (Immobilon-FL Millipore IPFL00010). Before membrane blocking, 
total protein was measured using the REVERT Total Protein Stain (LI-COR) and 
detected by NIR fluorescence at 700 nm (LI-COR Odyssey). The membrane was blocked 
for 1 hour (1% fish gelatin in TBS-T with 0.1 mM EDTA) followed by overnight 
incubation with primary antibody, at 4° C. The membrane was incubated with secondary 
antibody for 1 hour at room temperature then imaged on the LI-COR Odyssey. 
Quantification was performed using LI-COR Image Studio software and signal 
normalized to total protein signal. Normalization was calculated by dividing the total 
protein signal of each lane by the lane with the highest signal to gain the Lane 
Normalization Factor (LNF). The quantified signal for each protein band was divided by 






Cellular migration was measured using Oris Migration Assembly Kit (Platypus 
Technologies). Stoppers were placed in each well and cells seeded around the stoppers. 
The stoppers were removed after 2 hours and wells were imaged on the Cytation 5 
(Biotek). The cells were incubated for an additional 15 hours. The control cells were 
stained using CellTrace CFSE stain (ThermoScientific) for 20 min at 37° C then all cells 
were imaged as previously. The images were analyzed using Gen5 Software for mean 
GFP signal within the plug. The wells were quantified by subtracting the pre-migration 
signal from the post-migration signal. 
 
 
In vivo experiments 
Female nude (nu/nu) mice used in these experiments were obtained from Charles 
River Laboratories. Mice were allowed to acclimate for one week after arrival, prior 
undergoing orthotopic implantation of cells. Each mouse received 800,000 cells into the 
right mammary fat pad in a 50:50 solution of PBS and Matrigel Matrix (Corning Cat# 
354248). One group of mice received MDA-MB-231 cells (n=3) (tumor control mice) 
and another group of mice (n=3) received MDA-MB-231 CCT2 knockout cells. Mice 
were monitored for 60 days and once the tumor was large enough to be detected, caliper 
measurements were taken three times per week. The formula used for tumor volume 
measurements was length (mm) x width (mm) x 0.5). All animal work followed the study 
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protocol approved by the Institutional Animal Care and Use Committee (IACUC) at the 
University of Central Florida 
 
Statistical analysis and data mining  
For scoring analysis of TMAs one-way ANOVA was used to compare mean 
scoring between the different groups defined by various tissue parameters. Tukey’s 
multiple comparison test was used to compare significance between individual groups. 
Survival data was analyzed using Sidak’s multiple comparison test. Calculations were 
performed with GraphPad Prism software (GraphPad). Statistical significance was 
defined as p < 0.05. Breast cancer patient survival data in the current study is available in 






Increased CCT expression correlates with lower overall survival in breast cancer 
patients 
There are eight genes (cct1-8) that encode the subunits that form the CCT protein 
folding complex. To determine whether breast cancer patient survival correlated with 
increased gene expression of individual CCT subunits, we interrogated the breast cancer 
database available in the Kaplan-Meier plotter (n=3951). We found that while increased 
expression of all the subunits correlated with decreased patient survival, the most 
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statistically relevant results (p< 0.0026) were achieved for CCT2 (Fig. 18A-B).  A 
difference in survival of over 44 months was noted for patients that were high expressors 
of CCT2 compared to low expressers of CCT2 (Table 7). These results support our 
previous findings using The Cancer Genome Atlas (TCGA) database that increased 
expression of the CCT2 subunit is associated with decreased breast cancer patient 
survival [18] .We also found that CCT2 copy is increased across cancer cells lines 
(Project Achilles) and that CCT2 is an essential gene (Fig. 19A-C).  
 
 
CCT2 levels are higher in tissues of breast cancer patients when compared to normal 
breast tissue and correlate with levels of STAT3. 
We next examined a small cohort of archival tumor tissues (n=20) from patients 
with invasive ductal carcinoma (IDC) from a local hospital for protein levels of CCT2 as 
well as one of the CCT client proteins, STAT3. While CCT levels varied from low to 
high irrespective of cancer grade or stage, an almost 100% correlation between CCT2 and 
STAT3 levels was observed (Fig. 20A). We expanded this study to include commercially 
available tumor tissues from patients with advanced breast cancer, stage II or greater 
(n=160). Tumor tissues representative of scoring for CCT2 and STAT3 staining are 
shown in Figure 20D. We observed that CCT2 and STAT3 levels were low in normal 
tissues and increased in stage II or III breast cancer (Fig. 20B-C). When directly 
comparing CCT2 and STAT3 staining, we found that over 50% of the tumors had equal 
scores, that 37.6% of the tumors has scores that differed by only 1 score point and that 
11.4% of the tumors differed by 2 or more score points (Fig. 20E). This indicated that 
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88.6% the tumors had comparable levels of both CCT2 and STAT3, suggesting that more 
CCT2 could confer increased protein folding activity and provide more client proteins 
like STAT3 to cancer cells. 
 
Decreased levels of CCT2 leads to decreased levels of STAT3, while increase in CCT2 
leads to increased STAT3 
Based on the studies showing that CCT2 is an essential gene for cancer cells (Fig. 
19B-C), we opted for a knockdown of CCT2 in MDA-MB-231 breast cancer cells using 
CRISPR-CAS-9 technology. We previously showed that these cells had high levels of 
CCT subunits as compared to the breast epithelial cell line, MCF-10A [18]. Using a 
genomic cleavage assay, we achieved a 32% decrease in CCT2. This cell line showed a 
corresponding decrease in CCT2 protein and as well as a decrease in STAT3 (Fig. 21B). 
Next, using a lentiviral system, we generated a stable MCF-10A cell line that 
overexpressed FLAG-tagged CCT2. We confirmed both expression of the FLAG tag and 
increased CCT2 in the cell line and observed an increase in STAT3 (Fig. 22). Together 
these results, support that CCT2 is driving the levels of client proteins like STAT3 and 
could underlie the mechanism by which CCT promotes cancer progression. 
 
 
Increased expression of CCT2 stimulated cell migration, while decreased levels of CCT2 
reduced tumor growth in mice 
The overexpression of CCT2 in the non-tumorigenic breast epithelial cells, 
MCF10A, increased migration capabilities in these cells (Fig. 23A-B). MCF10A cells are 
immortalized but they are unable to form tumors in mice, these cells are sensitive to 
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confluency, nutrients and environment and can undergo spontaneous epithelial-to-
mesenchymal (EMT) transitions, a process that can also be induced by treatment with  
TGF-beta [98]. MDA-MB-231 cells are highly tumorigenic in mice. To determine if 
decreasing levels of CCT2 in the MDA-MB-231 influenced tumorigenicity, we used 
CRISPR/Cas9 with a gRNA targeting CCT2 to partially inhibit gene expression (Fig. 21). 
Cells were injected orthotopically in the mammary fatpad of female nude mice and tumor 
growth compared between wild-type (WT) MDA-MB-231 cells and CCT2 inhibited 
MDA-MB-231 cells. We found that tumors lacking CCT2 grew slower by 14 days (Fig. 
25) and were 2-5 fold smaller after 8 weeks (Fig. 25). These results show that even a 
partial loss (~32%) of a single CCT subunit, like CCT2, is sufficient to significantly 
impair tumor cell migration and tumor growth, indicating that inhibiting this protein 








Figure 18: High CCT expression levels significantly decrease survival in breast 
cancer patients 
Survival data in breast cancer patients showing that higher expression of all CCT 
subunits correlates with lower survival rates. (A) Bar graph of survival data showing that 
CCT3 levels have the highest effect on overall survival, but CCT2 levels have the most 
significance between high and low levels. (B) Kaplan-Meier plots of breast cancer 
patients based on the expression level of each CCT subunit. Numbers used to generate 
data is also on table 7. The survival graph was generated using publicly available 
database. Cohort size: 3951 patients (KM plotter; www.kmplot.com).  
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Table 7: Effect of high and low expression of each CCT subunit in survival of breast cancer patients 
 
Numbers used to generate data shown in Figure 18.  
CCT subunits
Low expression cohort 
(months)
High expression cohort 
(months)
Significant? Summary Adjusted P Value
TCP1 216.7 171.43 No ns 0.0594
CCT2 216.7 137 Yes ** 0.0026
CCT3 78.48 38.4 No ns 0.1032
CCT4 216.7 160.28 Yes * 0.0194
CCT5 216.7 161.43 Yes * 0.0216
CCT6A 228.85 184.04 No ns 0.0624
CCT7 216.7 168.5 Yes * 0.0438






Figure 19: CCT2 copy number and CCT2 essentiality in MDA-MB-231 cells  
Data and graphs obtained using publicly available databases (A) CCT2 copy number in 
cancer cell lines. Data from the Cancer Cell Line Encyclopedia (CCLE). Breast cancer 
cell lines have the highest copy number. (B-C) Data on CCT2 and essentiality in common 
cell lines (B) Achilles knockdown of CCT2 vs copy number and (C) Achilles knockdown 
of CCT2 versus mRNa expression showing essentiality of MDA-MB-231 cells [99]. 








Figure 20: CCT2 levels are significantly higher in breast cancer tissues than normal 
breast tissue and significantly correlates with STAT3 levels 
Human tissue derived from breast cancer patients were stained for CCT2 and Stat3 using 
immunohistochemistry. (A) Bar graph showing a strong correlation between levels of 
CCT2 and Stat3 on breast cancer tissue. Data obtained from local cohort samples (n=20). 
(B-C) Breast cancer containing medium to advanced stage breast cancer TMAs were 
purchased from USBiomax (cohort n=160). (B) CCT2 and (C) Stat3 staining scores. 
Tissue cores were analyzed by a pathologist according to stain intensity and given a score 
between 0-4 as previously published in Bassiouni et al (2016). (D) Graph of staining 
score results. Representative images of breast cancer TMA stained for CCT2 and Stast3 
indicating scores of 0, for normal breast tissue and scores of 1-3 for tumor tissue. All 
images were taken using  400X magnification. (E) Pie chart with percentage of scores 
that were identical (51%), differed by 1 point (37.6%) and by 2 or more points (11.4%).  
Significance indicated in graphs are in reference to normal tissue.).  * = p<0.05,   ** = 






Figure 21: Knockdown of CCT2 in MDA-MB-231 cells 
(A) The levels of CCT2 are reduced after stable transfection with CRISPR/Cas9 plasmid 
guide RNA 3. (B) Bar graph showing relative protein levels. CCT2 and stat3 levels are 
decreased after CRISPR/Cas9  (C) Total protein used for normalization. (CRISPR/Cas9 







Figure 22: Overexpression of CCT2 increases the levels of CCT client protein 
STAT3. 
Representative CCT2 and STAT3 blots of the control parental line and CCT2 
overexpression line show increased protein levels under normal growth conditions (n=1). 
(B) The relative protein levels of CCT2 and STAT3 are both increased after normalizing 
the signal to total protein. (C) Representative blot of the total protein used to normalize 
the CCT2 (left) and STAT3 (right) blots. (Transfection performed by A. Showalter and 






Figure 23: CCT2 overexpression cells migrate faster than the control line 
Cells were plated around 2mm plugs and allow to adhere for 2 hours. The plugs were 
removed and the cells were allowed to migrate for 15 hours before imaging. Reference 
wells for T=0 had the plugs removed prior to staining with CFSE and subsequent 
imaging. Fluorescent images of the reference wells were taken for T=0 and samples wells 
for T=15. (A) Control cells (n=4 wells) showed some migration after 23 hours. (B) CCT2 
overexpressing cells (n=4 wells) showed significantly more migration than the control 
cell line. (C) The mean GFP signal of cell within the 2 mm plug was measured with Gen5 
software using the following formula: (signal post-migration – signal pre-migration). The 





Figure 24: Overexpression of CCT2 in normal breast epithelial cells induces a 
change in morphology 
Representative images taken by Zeiss Axio Imager by phase contrast at 10X 
magnification. (A) MCF-10A, normal breast epithelial cells grow in small patches and 
remain mostly elongated. (B) CCT2 overexpression cells, as indicated by +CCT2, 




Figure 25: Knockdown of CCT2 decreases tumorigenicity of MDA-MB-231 cells in 
mice 
Female nu/nu mice received either control (n=3) or CCT2 knockdown cells (n=3) 
injected into the mammary fat pad. Tumors were allowed to grow and were measured by 
calipers three times a week starting once the tumor was palpable. (A) Over a period of 60 
days post-surgery, the control tumors grew large, with one being terminated early 
following the protocol. The CCT2 knockdown (KD) tumors remained smaller than the 
controls throughout the experiment. (B) The control tumors started to grow significantly 
earlier than the CCT2 knockdown tumors. Control tumors started to grow approximately 
18 days post-surgery while CCT2 knockdown tumors did not start growing until 





Using tools for genetic engineering, we generated cell lines in which expression 
of cct2 was inhibited or increased to show that the CCT protein folding complex was 
essential for the process of tumorigenesis. Full loss of CCT2 in breast cancer cells was 
lethal, and a partial loss resulted in reduced client proteins like STAT3 and decreased 
tumor growth in mice. Increased expression of CCT2 altered the morphology of breast 
epithelial cells, increased STAT3 levels, and promoted a migratory phenotype. In support 
of CCT2 as a promising therapeutic target, we observed increased levels of CCT2 protein 
in tumor tissues from patients with advanced breast cancer, which highly correlated with 
STAT3 levels. In contrast, CCT2 levels were undetectable to low in normal breast 
tissues.  Increased gene expression of CCT2 also correlated with decreased breast cancer 
patient survival.  These findings support further investigation of CCT2 as a promising 
biomarker for breast that could have diagnostic as well as prognostic potential. 
Group II chaperonins like CCT are found in the cytosol of archaea (e.g. 
thermosomes) and eukaryotes. CCT is evolutionarily conserved with multiple gene 
duplication events producing the eight subunits that form the two-ring complex[100]  
Each subunit has a unique position in the ring and substrates recognition is likely 
mediated through combinations of hydrophilic and hydrophobic interactions. What 
remains poorly understood is the level of redundancy or moonlighting for each CCT 
subunit. We observed that loss or overexpression of a single subunit, CCT2, was 
sufficient to alter the activity of the complex as reflected by the levels of client proteins 
like STAT3 and functional consequences such as migration and tumorigenicity. These 
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results suggest that individual CCT subunits are unique and could have multi-functions 
that are exploited by cancer cells. In support, others have shown that mutations in 
individual CCT complexes have divergent effects on cells. For example, mutation of 
CCT2 in yeast cells resulted in slower growth that was associated with a cell cycle defect, 
while mutations in CCT7 resulted in protein aggregations [101]. Such studies indicate 
that CCT subunits may each have unique roles related to substrate specificity but also the 
possibility that each subunit may have “moonlighting” functions independent of the 
complete complex. This is supported by our previous work and those of others using 
small interfering RNAs to inhibit individual CCT (iCCT) subunits, which suggested that 
iCCT subunits may have roles beyond protein folding, such CCT4 (epsilon) in the 
polymerization of F-actin [102] or CCT2 in promoting cancer cell growth [18, 41] 
That CCT has a prominent role in oncogenesis is evident in the increasing number 
of reports documenting the activity of the protein folding complex in the signaling 
pathways critical to malignancy such as the STAT family of transcription factors [28] as 
we show herein. Other CCT substrates important for cancer cell growth include cycle 
regulators and cytoskeletal proteins as well as proteins directly related to oncogenesis 
such as VHL and p53 Hence distinct CCT subunits are overexpressed in different 
cancers. In addition to our findings that CCT2 is highly expressed in advanced breast 
cancer, others have found CCT2 elevated in gall bladder carcinoma [70], colorectal 
adenocarcinoma [103] and heptacellular carcinoma [40]. Several groups found that CCT3 
expression was diagnostic in hepatocellular carcinoma [72, 79, 80], as well as CCT8 [39]. 
While this list is not extensive, it clearly demonstrates the growing trend that individual 
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CCT subunits are highly expressed in different cancers and could be important 
therapeutic targets. 
The discovery of CCT’s role in cancer progression has significant clinical 
implications in the development of personalized medicine for cancer therapy. Our data 
indicates that the CCT2 subunit could be a new biomarker for breast cancer that may be 
prognostic and help reveal when cancers progress and it could also be used as a 
companion or complementary diagnostic to guide therapies. In this regard, our lab 
developed a CCT inhibitor based on the capacity of an amphipathic peptide called CT20p 
[14, 104] to impair the chaperonin’s activity. Much of the functional consequences of 
loss of CCT2 that are reported herein, such as decreased tumorigenicity, also result upon 
treatment with CT20p [15, 18]. Hence being able to manipulate the levels of CCT2 in 
cells, as we have shown, not only establishes the importance of this protein folding 
complex in oncogenesis but also provides a tool by which we can further address the 
pressing questions on the roles of individual CCT subunits and the possible consequences 
(or lack of) of CCT inhibition upon normal, healthy cells. The biology of chaperonins 
like CCT is complex but its understanding could reveal new targeted approaches for 




CHAPTER 4: SMALL MOLECULE SCREEN DEVELOPMENT 






The first complete draft of this chapter was written by A.C.C. Comments from 
A.K were incorporated as it appears here. 
 







High throughput screens (HTS) are the backbone of drug discovery in the 
pharmaceutical industry as well as among academic researchers [105]. This type of 
screen encompasses testing a large number of compounds on a daily or weekly basis, for 
their biological effects. There are many types of HTS libraries including small peptides, 
small molecules, natural products and synthetic building blocks. In a target based 
approach, four crucial steps need to be considered in HTS design: target selection and 
validation; chemical hit and lead generation; lead optimization to identify a clinical drug 
candidate; and finally hypothesis‐driven, biomarker‐led clinical trials [106]. However, 
phenotypic screens are also used in instances where the target in unknown or targeted 
assays are not conducive with HTS.  
Based on data previously published by our lab, the mammalian chaperonin-
containing TCP1 (CCT) is an ideal candidate for target based drug discovery. We have 
showed that CCT is the intracellular target for CT20p, a cytotoxic peptide discovered by 
our lab [15, 18, 84, 107]. CCT is a macromolecular complex, composed of two rings 
stacked back-to-back, forming a barrel-like structure in which unfolded substrates are 
sequestered away from the cytosol until they reach their native conformation [62]. Each 
ring is composed of eight distinct, paralogous, subunits (CCT1-8). We identified targets 
of CT20p in a pull-down assay using biotin-CT20p. Proteomic analysis indicated CT20p 
interacts with seven out the eight CCT subunits [18]. We have also showed that in breast 
cancer cells, CT20p cytotoxicity correlates with CCT levels [18]. In addition, CCT levels 
have been shown to be higher in multiple cancers when compared to normal tissues [64] 
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The approach we developed and report here does not directly screen for CCT 
inhibitors, but it can be classified as target driven/phenotypic hybrid. Our primary, in cell 
assay uses a triple-negative (TNBC) cell line that stably expresses luciferase, therefore, 
decrease in luminescence can be caused by CCT inhibition, luciferase folding inhibition 
by direct interaction with the compound or cell death by an unrelated mechanism. 
Regardless of the MOA of the compound, every compound that met our luminescence 
signal decrease threshold (> 70%  signal loss) criteria was selected as a hit compound and 
moved to the next screen. 
In this manuscript, we report the results for a pilot screen involving a 2100 




Materials and Methods 
 
Cell culture and conditions 
MDA-MB-231/Luc cell line was purchased from Cell Biolabs, Inc. (AKR-231) 
and MDA-MB-231 cells were obtained from ATCC. The firefly luciferase gene was 
stably transfected into the cell line and placed under the CMV promoter. Cells were 
cultured in  Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% FBS 
(Gemini). MCF-10A (ATCC CRL-10317) cells were cultured in Mammary Epithelial 
Cell Growth Media using MEGM bullet kit (Lonza). All media contained 1% antibiotic 
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antimycotic solution (Corning). Cells were grown in a humidified 37C incubator with 
5% carbon dioxide. 
 
Reagents and small molecule library 
D-luciferin (Goldbio) was dissolved in 1X PBS at 15 μg/ml, filter sterilized using 
0.22 μm filter (Millipore) and stored in small aliquots in -20°C. Staurosporine InSolution 
(Calbiochem) stock concentration was 1mM, in DMSO. 
The 2100 compounds were purchased from Asinex and distributed in a 384 plate 
format. Compounds were in DMSO and the stock concentration was 10mM. Plates were 
stored in -80°C. 
 
 
Assay format, optimization and z’factor calculation 
Cell seeding density: The screen was performed using 96 well plates (white, 
PerkinElmer). To determine optimal seeding density and signal linearity, MDA-MB-
231/luc cells were seeded in two sets of triplicates at 1500, 3000 and 5000 cells per well. 
After 24 hours, spent medium was replaced with fresh medium containing 0.1μg/mL D-
luciferin. Plate was wrapped in aluminum foil and luminescence signal measured after 10 
minutes. This was repeated at the 48 hour time point as well.  
Controls: For this pilot screen, the positive control for luminescence signal loss 
was staurosporine, used at 0.5μM final concentration (Fig. 27A)  
Assay validation: The z’ factor determines the quality of the assay, taking into 
account only the controls used in the assay [108]. The z’ factor values range from 0 to 1, 
97 
 
values above 0.5 are considered excellent. We have determined the z’ factor to be 0.611 
for our assay. 
Secondary screen: To determine the effect of hit compounds on non-tumorigenic 
cells, MCF10A cells were seeded at 10,000 cells per well and treated with 10M for 48 





Primary screen identified 24 hits in a 2100 compound library 
Using a library composed of 2100 small molecules, we developed and optimized 
an in cell assay selecting for molecules that decreased luminescence signal by 70% or 
more in MDA-MB-231/luc cells. Compounds were tested at 10M in duplicate wells. 
Each test plate contained duplicates of positive and negative controls and signal from test 
compounds were normalized to internal controls (Fig. 27B).  
Both luciferase and luciferin are CCT clients, if the compound inhibits CCT, 
luciferase and luciferin will not fold properly and there will be a decrease in 
luminescence compared to the untreated control. Figure 28 summarizes the rationale for 






For a hit to move to the next phase of testing, it cannot have cytotoxic effects on 
normal cells. For that, we tested the 24 hit compounds on the non-tumorigenic MCF-10A 
cell line using the same concentration as in the primary screen. Only minimal cytotoxic 
effects were observed (Fig. 30A). 
 
 
Lead compound  
To identify the lead compound, we tested each of the 24 hits using an extended 
dose range from 2.5μM-40M. Standard MDA-MB-231 (non-luc) cells were seeded as 
described in materials and methods. Only one “hit”, the lead compound, killed the 231 










Figure 26: MDA-MB-231 cell seeding density optimization  
On a 96 well white plate 1500, 3000 and 5000 cells per well were seeded in triplicates. 
Luciferin was added and signal measured (A) 24 hours or (B) 48 hours. (C) Graph 




Figure 27: Assay plate set up showing position of positive and negative controls 
(A) Signal from negative (untreated cells) and positive (staurosporine) controls. 
Staurosporine is a protein kinase inhibitor and it causes cell death through a canonical 
apoptotic pathway. (B) Only the inside wells were used for this assay to avoid edge 
effects. The plate set up includes both controls in every plate so data normalization is 










Figure 28: Summary of the assay rationale 
The TNBC cell line, MDA-MB-231/luc stably expresses luciferase. Both luciferin and 
luciferase are folded by CCT. If CCT is inhibited by the small molecule in the screen, it 
will not fold luciferase properly and luminescence signal will be low. Each plate has both 
the positive and negative controls. The data is normalized to the internal controls per 






Figure 29: Representative structures identified in the screen.  
A) Structure identified as the lead compound B) Six of the 24 compounds identified in 





Figure 30: Lead compound secondary assays results  
(A) Bar graph showing the percent survival of normalized signal of lead compound 
effects at 10μM,  on control and TNBC cell lines using CellTiterGlo (B) Dose response 





Our drug screening strategy to identify novel CCT inhibitors was validated using 
a pilot 2100 compound library. We rationalized that because both luciferase and luciferin 
are known to be folded by CCT, although they are not obligate clients [94], if the 
compound inhibits CCT, we will observe a decrease in luminescence compared to the 
untreated control. The initial screen identified 24 hit compounds , equivalent to ~10% of 
the library [109], based on loss of luminescence. We expected that a few of these could 
be chaperonin inhibitors. Secondary screens revealed which of these compounds was not 
toxic to immortalized breast epithelial cells but still killed triple negative breast cancer 
cells. Counter screens showed which of these compounds did not induce a heat shock 
response but did trigger the membrane translocation of calreticulin (not shown). Based on 
these assays, we identified one hit that matched our criteria for a possible CCT inhibitor. 
To date, other than our CT20p peptide, no general use CCT inhibitors have been 
identified. There are only a few reports of CCT inhibitors based on hindering a specific 
interaction with a known client (e.g. tubulin [81, 82]) that have limited application.  
Hence our study would be the first to discover a CCT inhibitor that could have clinical 
use for multiple cancers. Disrupting molecular chaperones as a form of cancer therapy 
was first explored for HSP90. Hsp90 has received the most attention as a possible 
therapeutic target because it is upregulated during oncogenesis [83, 86, 88]. A number of 
small molecules and natural product inhibitors of HSP90 advanced to clinical trials.  The 
best known of these are geldamycin derivatives [110]. However, problems with induction 
of protective heat shock response and the inability to achieve therapeutic doses hampered 
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these trials [111]. Another approach for targeting proteins essential for cancer cells, is to 
inhibit the proteasome. Pathways for protein folding and ubiquitin-mediated proteolysis 
have a number of points of commonality. Proteasome inhibitors, like Veldcade, are 
currently used in the treatment of multiple myeloma [112]. Benefits were also observed 
with combination approaches of protein folding and proteasome inhibition, hence, our 
CCT inhibitor could be used to improve existing therapeutics in combination approaches. 
The typical screens used to identify agents that impair molecular chaperones are 
cell-based and involve loss of a chaperone-dependent activity. In one study, a v-src-
luciferase fusion was used as reporter and hits included HSP90 inhibitors, ubiquitin 
pathway inhibitors, histone deacetylase inhibitors and others, revealing one of the 
challenges of this approach when seeking an inhibitor that could impact many 
downstream substrates [113]. Hence, it becomes important to generate a strategy, as we 
described herein, to move from a general screen to one that is more specific for CCT.  As 
example, one group developed a method to purify the complete human CCT complex (all 
eight subunits) from HeLa cells. To confirm activity of the complex, a luciferase 
refolding was performed [114]. However, a more rigorous test was needed to ensure that 
the complex being isolated was indeed CCT, so an assay to measure aggregation 
suppression was also included [94]. However, this assay is tedious and time consuming 
and does not lend itself to high throughput. Our solution was based on characterizing the 
biological effects of CCT inhibition observed upon treatment with CT20p, such as the 
membrane translation of CRT and absence of GRP78 membrane translation, which can 
be assessed by flow cytometry. The latter was especially important as a counter screen, 
because most HSP90 inhibitors can cause GRP78 membrane exposure as part of 
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protective heat shock response. Future screens could also incorporate use cell lines that 
stably overexpress or inhibit CCT subunits as well as employ in silico drug screen 
technology to identify classes or families of compounds that can dock at the substrate 














CCT2 levels are significantly higher in prostate, hepatocellular, breast and lung 
cancers compared to normal tissues, indicating CCT as a potential biomarker in these 
cancers. CT20p is cytotoxic to SCLC cells but not normal lung tissue, therefore targeting 
CCT with CT20p in SCLC is a promising therapeutic approach. CCT levels are high in 
immortalized cell lines or cells lines that have undergone EMT, but the same is not 
observed in normal human tissue, therefore immortalized or transformed cell lines cannot 
be used as control for CT20p experiments. When CCT is inhibited, levels of client 
proteins, such as STAT3 decreases, indicating CCT targeting has the potential to inhibit 
many pathways involved in oncogenesis. Partially knocking out CCT2 in MDA-MB-231 
cells, a highly tumorigenic triple negative cell line, is sufficient to decrease 
tumorigenicity potential in nude mice. Overexpressing CCT2 in immortalized breast 
cells, increases migration and causes morphology to change, two characteristics of cells 




CCT2 levels is a biomarker in many cancers 
Using patient tissue microarrays containing 80-120 cores each, we determined 
CCT2 levels in a large number of samples in prostate, colon, liver, breast and lung 
cancers by immunohistochemistry. We were also able to correlate CCT2 levels with 
stage, severity, and histological characteristics in these TMAs, allowing us to conduct a 
broad analysis of CCT2 in the most common cancers affecting the population today. We 
found that CCT was significantly higher in advanced tumors when compared to normal 
109 
 
tissue. SCLC stood out by having the highest CCT2 levels among the cancers analyzed in 
our study. We used publicly available genomic databases and found that all CCT subunits 
are expressed at higher levels in breast cancer and that higher levels correlate with 
decreased survival. The CCT subunit with the most significant effect on patient survival 
was CCT2, which indicates that this subunit has an essential role in breast cancer 
progression, which is validated by previous work published by us and others [18, 41, 70]. 
 
 
Targeting CCT with CT20p in SCLC is a promising therapeutic approach  
Using five SCLC cell lines, we showed that CT20p is cytotoxic in a dose 
dependent manner and that cytotoxicity levels vary among cells lines, indicating that 
there’s a therapeutic window which allows for effective eradication of tumor cells while 
sparing non- cancerous ones. 
Client proteins, such as STAT3, also respond to CCT inhibition to different 
degrees in a cell line dependent fashion. Targeting CCT is a rational approach because 
cancer cells express and rely on the chaperonin more heavily than normal cells. Rapidly 
proliferating cells, such as during development and spermatogenesis, have higher levels 
of CCT than non-proliferating cells, as it has been shown in a previous study done using 
mice [115, 116]. Using siRNA to deplete CCT causes cell cycle arrest in Swiss 3T3 
mouse fibroblasts indicating CCT has an essential role in cell cycle progression[102]. In 
this same study, CCT’s folding activity was modulated by using an antibody against 
CCT5 which caused loss of cell motility and cytoskeletal disorganization [102]. Similar 
effects were observed in studies by our lab on CT20p effects on breast cancer cells [18]. 
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Other CCT inhibitors include arsenic and N-iodoacetyl-tryptophan (I-Trp) [81]. Arsenic 
inhibits CCT and impairs actin and tubulin filaments [81, 85]. I-trp is a synthetic small 
molecule derived from iodoacetamide capable of interrupting the constitutive β-
tubulin/CCT2 interaction eliciting caspase-dependent signaling which leads to cellular 
apoptosis [82, 83]. An advantage of CT20p, is that cell death is caused independently of 
the canonical apoptotic pathway [14], which is often downregulated in tumor cells, 
instead, CT20p prevents folding of many tumor essential proteins therefore, halting 
tumor progression [84]. Targeting CCT, a chaperonin responsible for folding many 
oncogenic proteins, is advantageous in the sense it decreases the pool of essential proteins 
required for tumor progression.  
 
 
CCT2 plays a role in oncogenesis 
The TNBC cell line MDA-DB-231 is a highly tumorigenic and commonly used to 
investigate growth and metastasis of human breast cancer in vivo, by xenograft 
transplantation in immunocompromised mice [117]. By partially knocking out CCT2 
using CRISPR/Cas9, tumor development was delayed by about 2 weeks compared to 
control cells. We were unable to obtain complete CCT2 knock out cell lines because full 
loss of CCT2 in this cell line was lethal. In addition to decreasing tumor growth in mice, 
partial loss of CCT2 also resulted in reduced client proteins like STAT3. These results 
agree with previous work that found CCT to be overexpressed in cancer cells compared 
to non-cancerous cells, with notably high expression in MDA-MB-231 cells [64], 
suggesting this cell line has a higher CCT dependency for growth and survival.  
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Overexpressing CCT2 in immortalized, untransformed breast epithelial cells 
induced morphological changes and increased migration, a phenotype also observed in 
this cell line when it undergoes EMT, suggesting that CCT could have a role as a driver 
of oncogenesis.  
The role of CCT complex in oncogenesis has not been extensively explored yet, 
but there is an increasing trend in recently published work suggesting that CCT’s role in 
cancers could be cancer specific. In addition to our findings on CCT2 overexpression in 
breast cancer, others have reported CCT2 to be elevated in gall bladder carcinoma [70], 
colorectal adenocarcinoma [103] and hepatocellular carcinoma [40]. Also in HCC, CCT3 
was determined to be diagnostic in hepatocellular carcinoma [72, 79, 80], as well as 
CCT8 [39, 40]. Together, these data suggest that there might be a CCT subunit/cancer 
type correlation that should be further explored since understanding this relationship 
would help elucidate the process of oncogenesis and ultimately lead to better therapies.  
 
 
The search for small molecules inhibitors of CCT 
We developed an in cell, luminescence based assay for rapid screen of small 
molecules able to inhibit CCT and/or luciferase folding in TNBC cells. The assay was 
considered optimal based on the high z’factor obtained (z’factor =0.6) [108]. In a period 
of 2 months, 2100 small molecules were screened, in duplicates, yielding 24 hits. The 
number of hits obtained by this assay further validates our approach, since robust HTS 
assays are expected to yield 10% of the total number of screened molecules as hits. 
Secondary screens identified one lead compound which caused cell death in a dose 
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dependent manner in TNBC cells but only minimally affected immortalized breast 
epithelial cells. Unfortunately, the structure associated with the lead compound was 
inaccurate and we were unable to continue further characterizing of the lead molecule. 
Nonetheless, in this study, we developed and validated a high throughput screen assay 
that is relatively simple, cost effective and scalable, consequently establishing a new 
platform for the screening of larger libraries for potential inhibitor of CCT. Future studies 
will focus on developing an in vitro companion and/or secondary assay focused on CCT 
activity. Luciferase folding assay is commonly used to test CCT activity [61, 94], as a 
companion assay, it would be possible to screen for CCT inhibitors by combining results 
from the in vivo with the in vitro components by setting more lax thresholds and only 
considering the compounds above both thresholds as “hits”. Alternatively, the in vitro 
component would serve as a secondary assay, for inhibitors of CCT that directly contact 
at least one of the eight subunits, thus, only true CCT inhibitors would continue further 
characterization. The approach we used to screen for CCT inhibitors in vivo using TNBC 
cell lines that stably express luciferase can be adapted to any cancer cell line capable of 
stably expressing luciferase, thus, the impact of this work expands well beyond breast 
cancer and could impact an array of different cancer types.  
 
Concluding remarks  
The discovery of CCT’s role in cancer progression has crucial clinical 
implications in the development of personalized medicine for cancer therapy. TNBC and 
SCLC, both aggressive, highly metastatic cancers that currently lack efficient treatments, 
have the potential of being detected earlier by using CCT2 levels in biopsies and treated 
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effectively by targeting CCT as a therapeutic approach. Other cancers, such as prostate 
and hepatocellular can also benefit from CCT targeted therapies. Therefore, the findings 
presented in this dissertation provide a broad impact in the cancer field of research which 
can be translated into the clinic and ultimately on patients affected by these cancers. 
Because CCT subunits have different specificities and reports have shown they have 
different roles in several different disease states, understanding the role of each CCT 
subunit in normal cells as well as their role in different cancers is imperative and it will 
allow for rational drug design, tailored to each cancer type, with improved targeting 
capabilities and decreased off target effects. As an alternative, the development of 
medium and high- throughput screens aimed to identify CCT inhibitors in many cancers, 
such as the one presented in this dissertation which used TNBC cells, could yield novel 
therapeutics in a faster time-scale. Altogether, the work presented in this dissertation 
demonstrates the feasibility of CCT as a biomarker in many cancers, especially SCLC, 
the use of CT20p as a cancer therapeutic and that CCT2 has an essential role in cancer 
progression, significantly contributing to overall body of knowledge in the cancer field. 
Future work is focused on elucidating the inhibitory mechanism of CT20p at the cellular 
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